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ROLE OF HNRNP H IN A REVERSIBLE FINE-TUNING MECHANISM OF 
SPLICING RESPONSE UPON TRANSCRIPTIONAL PAUSING 
Erkan Bayir, M.Sc. 
University of Pittsburgh, 2016 
Alternative splicing is a common way of diversifying the proteome and regulating protein 
functions without increasing genome size. Chemotherapeutic agents, such as cisplatin, 
cause changes in the splicing of proliferation-associated exons, which contribute to the 
overall proliferative phenotype of cancer cells. Transcriptional pausing, which is seen in 
embryonic stem cells as a timing regulator of gene expression, also impacts splicing. 
The mechanisms by which transcriptional pausing and pause-release alter the functions 
of splicing machinery are largely unknown. Thus, I tested the effects of the transcription 
elongation inhibitor DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) on the splicing 
of a set of inducible exons with a common UAGG-GGGG splicing code. These exons 
were previously identified through a genomewide search for the transcripts sensitive to 
hnRNP A1 and hnRNP H. I found that the endogenous human HNRNPH1 Exon 4 and 
its paralog HNRNPH3 Exon 3 had increased skipping upon DRB treatment, as did the 
pA+ reporter-cloned GRIN1 CI, a brain-region-specific rat exon with this splicing code, 
previously studied in our lab. I used single and combined mutations to monitor the effect 
of DRB-induced transcriptional pausing and pause-release on splicing, since the shared 
motifs include two exonic UAGG motifs and a GGGG close to 5´ splice site. GGGG 
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mutants had increased skipping, compared to wild type, upon DRB treatment. UAGG-
GGGG code is necessary for the response, as the triple mutant lost its ability to respond 
to DRB. These data point to a role of hnRNP H in response to transcription stress. 
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1.0  INTRODUCTION 
Splicing is an important mechanism in the processing of eukaryotic pre-mRNAs, in 
which the non-protein-coding introns are removed and exons are spliced, thereby 
producing the mature mRNA. Splicing is controlled by different cis- and trans-acting 
elements, namely the enhancer and silencer RNA motifs acting in cis, and splicing 
factors acting in trans, to regulate the inclusion or skipping decision of an exon and 
defining the intron and exon boundaries. 
Splicing factors are the proteins encoded by particular genes, and changes in 
their expression alter the splicing of a transcript under the control of these splicing 
factors. The stoichiometry of splicing factors in a cell can be different across tissues, 
and developmental stages, can differ before and after signal transduction, all of which 
result in multiple alternatively spliced isoforms of the same transcript (Stamm, 2002; 
Lipscombe, 2005; Boutz et al., 2007; Zhang et al., 2008). 
Alternatively spliced isoforms of the same transcript give rise to different proteins, 
regulating the structure and function of proteins as well as diversifying the proteome 
without the need to increase the size of the genome. Since splicing factors are also 
encoded by genes, the transcripts of splicing factors are also subject to alternative 
splicing. The processes of transcribing and splicing a pre-mRNA transcript are spatially 
and temporally linked, suggesting a crosstalk or common regulation of both processes. 
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Splicing is regulated in response to a plethora of inputs, and this regulation provides a 
strategy for cells to adapt to environmental challenges and respond to different types of 
cellular stress. 
1.1 SPLICING AND TRANSCRIPTION 
Transcription of DNA into pre-mRNA by the RNA polymerase II enzyme has initiation, 
elongation and termination steps; which are all coupled to RNA processing. The 
coupling of transcription and RNA processing is especially important in splicing, a 
complex molecular mechanism of RNA modification in eukaryotic cells. Splicing and 
transcription are coupled, due to the C-terminal domain (CTD) of RNA polymerase II. 
The phosphorylation of serines in the CTD is important for the movement of RNA 
polymerase II on the DNA (Phatnani and Greenleaf, 2006) and it also associates some 
of the splicing factors that are transferred from CTD onto the nascent RNA (David et al., 
2011; Hsin and Manley, 2012). The transcription-splicing coupling and the effect of this 
coupling on the splicing of several genes raised questions about whether there are 
proliferation-associated genes among the targets of this coupling, that might have an 
effect on proliferation, differentiation or the overall phenotype. 
1.1.1 RNA Polymerase II C-terminal domain and coupling 
A comprehensive proteomic analysis of immunopurified human RNAP II-coupled factors 
by mass spectrometry revealed that SR proteins and U1 snRNP are associated with 
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RNAP II, suggesting that SR family of splicing factors and U1 snRNP have a role in 
splicing-transcription coupling (Das et al., 2007). The transcription initiation factor TFIIH 
was found to “specifically associate” with the spliceosome component U1 snRNP (Kwek 
et al., 2002). The phosphorylation by TFIIH kinase CDK7 is also important due to its role 
in promoter-proximal pausing, and its inhibition by the specific inhibitor THZ1 causes the 
failure of capping and pausing (Nilson et al., 2015). Many cancer types are responsive 
to THZ1 treatment, showing its potential as a cancer drug (Jeronimo et al., 2016). 
There are possible ways of crosstalk between transcription and splicing that are 
previously proposed, such as recruitment coupling (de la Mata et al., 2006) and kinetic 
coupling (de la Mata et al., 2003). Histone modifications, important in transcription, were 
found to be differentially associated with the splicing pattern of PTB-regulated exons, as 
another possible way of crosstalk between transcription and splicing (Luco et al., 2010). 
 CDK12, which is capable of phosphorylating all serines in the RNA polymerase II 
CTD, was shown to have an affect on the alternative splicing of the SRSF1 gene (Liang 
et al., 2015). Since the CDK12 is required for Ser2 phosphorylation in different species, 
and Ser7 phosphorylation stimulates CDK12 activity, it can constitute the link between 
the transcription and splicing (Jeronimo et al., 2016). 
Transcriptional stress can affect the splicing by severing the coupling between 
transcription and splicing. Human nuclear cofactor TCERG1 was suggested to be a 
possible coordinator of transcription and splicing (Montes et al., 2012) and its mobility 
decreased upon DRB-induced transcription elongation inhibition (Sánchez-Hernández 
et al., 2016). Splicing-transcription coupling appears as an important way of splicing 
control, causing changes in the splicing of many exons that are subject to regulation. 
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1.1.2 The role of cis-regulatory RNA elements in splicing 
The splicing machinery needs to recognize the consensus sequences at the 5’ and 3’ 
splice sites and the branchpoint in order to define introns and exons. Most mammalian 
major-spliceosome introns start with GU at the 5’ splice site, and end with an AG at the 
3’ splice site (Sheth et al., 2006). Transcripts have intronic and exonic sequences, the 
cis-regulatory RNA elements, contributing to the selection of a particular splice site. 
The enhancer and silencer sequences, depending on whether they are located 
within the intron or exon, are named as the intronic splicing enhancers (ISE), intronic 
splicing silencers (ISS), exonic splicing enhancers (ESE), and exonic splicing silencers 
(ESS). The copy number and the spatial arrangement of these short RNA elements is 
important, because the effect of regulatory RNA elements is dependent on the strength 
of the enhancer or silencer effect in a context-dependent way (Fu and Ares, 2014). 
The combination of cis-regulatory RNA elements, or the splicing code, has a role 
in adjusting splicing patterns through interactions with the splicing factors (Wang et al., 
2008). When an RNA element is bound by trans-acting splicing factors, it has a role in 
the decision on whether an exon will be included or skipped. 
1.1.3 Trans-acting splicing factors and their functions 
Splicing factors are proteins that bind to RNA elements with some degeneracy via their 
RNA recognition motifs (RRM). The combined effect of cis-acting RNA elements and 
trans-acting splicing factors is important, because they act in an orchestrated way, not 
as one single cis-regulatory RNA element or one splicing factor causing the inclusion or 
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skipping of an exon. Therefore, the resulting pattern of splicing for a particular exon is 
an equilibrium that is subject to the composite effect of the splicing activators and 
splicing repressors, binding to the enhancer and silencer RNA elements. 
Serine- and arginine-rich SR proteins are an important family of splicing factors, 
performing many functions. Spliceosome components U1 and U2 snRNPs are recruited 
to and stabilized at the splice sites by SR proteins (Feng et al., 2008). Having an 
arginine- and serine-rich RS domain, SR proteins can come together with other RS-
containing splicing factors and act as splicing enhancers (Chen and Manley, 2009). 
Their function depends on the sequence and location of the cis RNA motifs, and post-
translational modifications like phosphorylation. Many SR proteins are phosphorylated 
and activated, and their dephosphorylation causes their nuclear export (Stamm, 2008). 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a family of splicing 
factors that have RNA recognition motifs (RRMs), and they often act as splicing 
repressors upon binding to silencer RNA sequences (Ladd and Cooper, 2002). 
Although many hnRNPs generally cause exon skipping, they sometimes favor an 
alternative cryptic or weak splice site (Matlin et al., 2005). Splicing repressors can block 
the splicing factor binding to splicing enhancers, or block the splice sites by steric 
hindrance so that the spliceosome cannot be assembled (Chen and Manley, 2009). For 
instance, hnRNP A1 interferes with the U1 snRNP binding to the 5’ splice site (Eperon 
et al., 2000). Close to the 3’ end of the CD45 exon 4, hnRNP A1 and U1 snRNP cause 
exon skipping in an hnRNP L-dependent manner (Chiou et al., 2013). The effects of 
different splicing factors on a particular exon contribute to the final balance, leading to 
the inclusion versus skipping decision. 
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1.2 SPLICING-RELATED DISEASES: HEALTH IMPACTS 
Pre-mRNA splicing is subject to regulation in response to different inputs, and the 
proteins that are made as a product of the aberrant splicing of certain transcripts can be 
detrimental to human health. Some of the aberrant splicing patterns were previously 
characterized in various diseases, such as neurodegenerative diseases and cancer. 
There are cis-acting mutations on DNA that change the splice sites or create new 
splice sites, and there are trans-acting factors that can cause changes in splicing, which 
contribute to the development of diseases caused by aberrant splicing patterns (Ward 
and Cooper, 2010). The splicing change that causes a disease can be exploited to 
elucidate the splicing mechanism and develop a splicing therapy. If the aberrant splicing 
is reverted to the normal splicing pattern, the disease phenotype can be ameliorated. 
There are different RNA-based therapeutic approaches for splicing-related 
diseases. The use of antisense oligonucleotides aims to revert the splicing from the 
splice isoform causing the disease to an isoform that rescues the phenotype (Sazani 
and Kole, 2003). RNA interference that specifically targets an aberrantly-spliced mRNA 
decreases the protein that contributes to disease, and small molecules that interfere 
with the splicing factors or RNA secondary structures can alter the aberrant splicing 
patterns associated with the disease (Cooper et al., 2009; Scotti and Swanson, 2016). 
1.2.1 Alternative splicing in cancer and early tumorigenesis 
One of the most important diseases associated with aberrant splicing patterns is cancer. 
There are many cancer-related changes in splicing as a result of, or in the absence of 
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genomic mutations. Splice site mutations cause aberrant splicing in cancer (Venables, 
2004). Splicing factors are subject to mutations that can cause cancer-related changes 
in splicing (Scotti and Swanson, 2016). The splicing of some genes is developmentally 
regulated, and they are preferentially re-expressed in cancer (David and Manley, 2010). 
Mutations close to splice sites can lead to aberrant splicing of tumor suppressor genes, 
promoting cancer (Supek et al., 2014). Tumorigenesis-associated exons with similar 
splicing changes were identified in several human tumors (Danan-Gotthold et al., 2015). 
Cancer cells are not individual cells that are isolated from their environment; they 
rather co-evolve altogether upon exposure to different kinds of stresses. There are 
interactions between cancer cells, and the evolution of the tumor is a collective and 
programmed response performed by interacting cells (Lambert et al., 2011). The 
external stress is beneficial to the tumor cell population as a whole, and possible 
changes in splicing caused by different kinds of stresses are exploited as a strategy for 
sustaining and expanding the tumor. 
The link between cancer and splicing is extensively studied, and these studies 
aim to identify a set of cancer cell-specific splice isoforms along with significant changes 
in splicing associated with early tumorigenesis. The cancer-related changes in splicing 
are important in early tumorigenesis. Some of the causes of early tumorigenesis, such 
as genotoxic stress, possibly have a significant impact on splicing. The elucidation of 
alternative splicing in early tumorigenesis can be exploited to develop an RNA-based 
system of therapy to reprogram splicing and slow down cancer progression. 
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The pyruvate kinase M2 (PKM2) isoform, a product of alternative splicing, is 
subject to allosteric regulation by fructose-1,6-bisphosphate and phosphotyrosines, that 
causes the pyruvate kinase enzyme (encoded by PKM2) to be dimerized and diverting 
the pathway to the synthesis of biomolecules, which is needed by rapidly-dividing fetal 
and cancer cells (Christofk et al., 2008). The glycolytic metabolism was proposed to be 
an adaptation of cancer cells during early tumorigenesis, in which blood vessels are not 
formed yet, and the oxygen is scarce (Cairns et al., 2011). 
EGFR, CD44, NER, tyrosine hydroxylase, lactate dehydrogenase, cadherin-11, 
fibronectin, and Brn-3a were reported to have cancer-associated splice variants, and it 
was suggested that splicing changes might be widespread in human cancers (Xu and 
Lee, 2003). Bcl-x alternative splicing gives rise to a pro-apoptotic Bcl-xS and an anti-
apoptotic Bcl-xL isoforms, and high Bcl-xL expression was associated with many 
cancers as a possible way of cancer cells to escape apoptosis (Bauman and Kole, 
2011). Cyclin D1, H-Ras, and VEGFA pre-mRNA transcripts are subject to alternative 
splicing with respect to apoptosis and cancer (David and Manley, 2010). Cancer-related 
splicing defects can be targeted to revert splicing by the use of RNA oligonucleotides. 
An alternatively spliced variant of the gene encoding spleen tyrosine kinase was 
found to be frequently expressed in breast cancer tissues, and this splice variant was 
never found in normal mammary tissues (Wang et al., 2003). SF3B1, encoding a core 
member of U2 snRNP complex, was observed to be mutated in 15% of 91 patients that 
have chronic lymphocytic leukemia, which shows that spliceosome components might 
also be subject to mutations in cancer (Wang et al., 2011). More commonly observed 
splice variants can be used as markers for different types of cancers. 
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1.2.2 Neurological disorders and aberrant splicing patterns 
There are several neurological disorders, which result from aberrant splicing in neuronal 
cells. For instance, a single nucleotide substitution in SMN2 (survival of motor neurons) 
gene, which encodes the SMN protein, causes spinal muscular atrophy disease due to 
exon skipping (Lefevbre et al., 1995). SMN complex is important for snRNP biogenesis, 
and the abnormal splicing of SMN2 can affect splicing globally (Cooper et al., 2009). 
A deletion in the ATM gene intron 20 causes a cryptic exon to be included, and 
this splicing change causes ataxia-telengiectasia (Pagani et al., 2002). Duchenne 
muscular dystrophy is also among the diseases partially caused by splicing defects in 
dystrophin gene, and a nonsense mutation resulting in partial skipping of exon 31 was 
identified to contribute to the disease (Disset et al., 2006). 
Cystic fibrosis transmembrane conductance regulator (CFTR) splicing defects 
caused by a tryptophan deletion were seen in about half of the cystic fibrosis patients in 
the US (Cooper et al., 2009; Scotti and Swanson, 2016). Neurological disease-related 
splicing changes provided the opportunity to elucidate the splicing mechanisms of these 
transcripts, and possible ways to exploit the splicing machinery to develop therapies. 
1.3 ALTERNATIVE SPLICING, STRESS AND PAUSE-RELEASE 
The splicing of many genes is altered in response to different kinds of cellular and 
metabolic stress such as oxidative stress, heat shock, and hypoxia (Biamonti and 
Caceres, 2009). Upon heat shock, various splicing factors are localized in nuclear 
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stress bodies, the active transcription sites that are suggested to act as rapid inducers 
of gene expression changes involving chromatin remodeling, transcription and splicing 
factor recruitment (Biamonti and Vourc’h, 2010). The phosphorylation of SR proteins is 
monitored upon heat and osmotic stress through cyclin dependent-like kinases Clk1/4 
(Ninomiya et al., 2011). Heat shock globally inhibits the splicing of posttranscriptionally 
spliced transcripts, whereas the transcripts including G-rich motifs in their introns are 
enriched among unaffected transcripts (Shalgi et al., 2014). 
 Calcium (Ca2+) signaling is particularly important for splicing in brain and neurons 
as well as with respect to the endoplasmic reticulum (ER) stress. An RNA element that 
is responsive to Ca2+/calmodulin-dependent protein kinase (CaMK) is involved in the 
neuronal depolarization-induced splicing changes in GH3 cells and neurons (Xie and 
Black, 2001; Xie et al., 2005). HnRNP A1 is phosphorylated by MAPK and relocalized to 
stress granules upon osmotic stress, by which ionic concentration changes can affect 
splicing (Allemand et al., 2005). Thus, cis-regulatory RNA elemens and trans-acting 
splicing factors can both be responsible for the Ca2+-mediated regulation of splicing. 
Genotoxic stress, especially by DNA damage inducing agents and irradiation, 
has an important role in splicing. Akt/PKB is particularly important in the response to 
genotoxic stress. ATM, ATR and DNA-PK activate Akt upon genotoxic stress (Viniegra 
et al., 2004; Bozulic et al., 2008). Activated Akt affects the SR splicing factors through 
SRPKs that phosphorylate SR proteins, and the EGF signaling regulates global splicing 
through Akt and SRPK (Zhou et al., 2012). 
 UV-induced changes in splicing are widely studied, and they can affect exon 
inclusion or skipping via causing changes in hSlu7 subcellular localization (Shomron et 
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al., 2005), through RNA polymerase II CTD hyperphosphorylation (Muñoz et al., 2009) 
or elevation of SRSF1 (Comiskey et al., 2015). 
Transcriptional stress can take place as a result of, or independent from 
genotoxic stress, and it also affects splicing. Transcriptional pausing and pause-release 
are likely to affect splicing due to the transcription-splicing coupling, or the splicing 
changes associated with transcriptional pausing and pause-release can be under the 
control of DNA damage response (DDR) pathways. 
1.3.1 Alternative splicing upon genotoxic stress 
Genotoxic stress can affect splicing by different ways; by post-translational modification 
of splicing factors, changing their cellular localization, transcriptional activation of 
splicing factors, or changing the rate of transcription (Thomas and Lieberman, 2013). 
Cisplatin is a cytotoxic anticancer drug that targets DNA by forming adducts. It 
forms intrastrand (and to a lesser extent interstrand) DNA crosslinks between purines, 
and alters the 3D structure of the double helix by causing DNA bending (Jung et al., 
2007). Thus, cisplatin causes inhibition of replication and transcription. 
 
 
cis-diamminedichloridoplatinum(II) (Cisplatin) 
 
 12 
Cisplatin and doxorubicin, two well-known cancer chemotherapy drugs, cause a 
change in CDC25C C1/C5 splicing, to shift from C1 to C5 in MCF-7 cancer cells, due to 
the genotoxic effects of these drugs (Albert et al., 2012). In a large-scale proteomic 
analysis of the proteins that are phosphorylated in response to DNA damage, many 
DNA damage response (DDR) signaling proteins and some of the splicing factors were 
found as targets of ATM and ATR kinase phosphorylation, and their phosphorylation by 
ATM and ATR can affect the splicing of their targets (Matsuoka et al., 2007). 
Cisplatin-induced DNA damage, which alters the double helix, is recognized by 
the cell and that initiates different DNA damage response pathways. The most important 
pathway that handles cisplatin-induced DNA damage is the “nucleotide excision repair 
pathway” (Basu and Krishnamurthy, 2010). Transcription-coupled repair is induced by 
the stalling of RNA polymerase II, and it is one of the ways that cells deal with cisplatin-
induced genotoxic stress (Damsma et al., 2007). The transcriptional elongation inhibitor, 
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), damages the DNA and triggers 
homologous recombination repair (Stoimenov et al., 2011). DRB-induced transcriptional 
pausing, similar to genotoxic stress, affects the splicing of many transcripts. 
 
 
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) 
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One of the possible ways that cisplatin treatment affects splicing is the 
crosslinking of the RNA component of snRNPs. Aquated cisplatin was shown to cause 
the crosslinking of guanines on the opposite sides of an internal loop, which is derived 
from U2:U6 spliceosomal RNAs (Hostetter et al., 2009). 
There are a number of studies that focus on global proteomic changes in HeLa 
cells upon cisplatin treatment. The hnRNP H was found to be upregulated, whereas the 
hnRNP C was downregulated, in the nuclear extracts of cisplatin-treated HeLa cells (Wu 
et al., 2010). In another study, the nuclear extracts of cisplatin-treated cells had a 
decrease in the hnRNP A1, hnRNP C1/C2 and hnRNP F levels, and an increase in the 
hnRNP K levels (Zhang et al., 2012). The global or specific alterations of splicing as a 
result of cisplatin treatment can affect the proliferative phenotype of cells. 
Genotoxic stress can affect splicing via transcriptional activation of splicing 
factors. The methylmethanesulfonate- and cyclophosphamide-induced genotoxic stress 
(caused by interstrand DNA crosslinks) were found to result in the upregulation of E2F1 
and E2F1-dependent SRSF2 (SC35) upregulation, and it caused an increase in the 
proapoptotic spliced isoforms of caspase 9 and Bcl-x (Merdzhanova et al., 2008). Thus, 
SRSF2 seems to be a candidate through which genotoxic stress can alter the splicing 
patterns of proliferation-associated transcripts. 
Genotoxic stress-induced cotranscriptional exon skipping was observed in some 
transcripts, among which the genes encoding splicing factors are also present (Dutertre 
et al., 2010; Solier et al., 2010). Topoisomerase inhibitors, which inhibit topoisomerase I 
and cause the stalling of DNA replication and transcription, cause genotoxic stress and 
affect the alternative splicing. For instance, topoisomerase inhibitor camptothecin 
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caused the skipping of multiple exons in MDM2 transcripts independent of p53 (Dutertre 
et al., 2010). 
Another molecule, topoisomerase II inhibitor mitoxantrone, caused relocalization 
of hnRNP A1, SRSF1 and SRSF2 to nuclear stress granules, resulting in a change in 
CD44 splicing (Busa et al., 2010). Topoisomerase 1 was recently found to be regulated 
through the CTD phosphorylation of RNA polymerase II during transcriptional pause 
release (Baranello et al., 2016), which can be one of the links that connects the effects 
of genotoxic and transcriptional stress on alternative splicing. 
1.3.2 Transcriptional inhibition and pause-release 
Transcription is regulated in response to many different environmental or developmental 
inputs, to adapt to surrounding conditions. The time and scale of gene expression can 
be adjusted throughout development, in different stages and locations, under the effect 
of different signaling pathways. RNA polymerase II transcribes mRNA from genes, and 
it is one of the means through which the mRNA transcription is modulated. 
Transcription has the initiation, elongation, and termination steps. In the initiation, 
RNA polymerase II binds to the promoter. In many genes, RNA polymerase II pauses at 
the promoter. The genes encoding the heat shock proteins (Hsp), which are important in 
the response to several types of cellular stresses, were among the first genes to be 
shown to have transcriptional pausing in Drosophila (Rasmussen et al., 1993). Pausing 
was also observed in the proliferation-associated human MYC and FOS genes, which 
had RNA polymerase II pausing at promoter-proximal regions (Plet et al., 1995). 
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Human and mouse embryonic stem cells have RNA polymerase II pausing in a 
significant portion of their genes, estimated to range from 30 to 90 per cent (Gilchrist et 
al., 2010). Thirty per cent of all genes were found to have RNA polymerase II pausing in 
human embryonic stem cells (Guenther et al., 2007), Drosophila and human primary 
cells, which seems to be the percentage of genes that show transcriptional pausing 
regardless of the species and cell type (Core et al., 2008). 
There are factors associated with RNA polymerase II promoter-proximal pausing 
that inhibit transcription elongation in vitro. DRB-sensitivity inducing factor (DSIF) and 
negative elongation factor (NELF), along with some additional factors have an effect on 
RNA polymerase II pausing (Narita et al., 2003). NELF knockdown released the paused 
polymerase, supporting the role of NELF in transcriptional pausing (Muse et al., 2007). 
The pausing factors themselves are subject to phosphorylation by kinases, as a 
means of regulating the pausing of RNA polymerase II. The phosphorylation of NELF 
and DSIF by the positive transcription elongation factor b (P-TEFb) results in the 
release of NELF from the complex and turning DSIF into a factor favoring transcription 
elongation, making it a positive factor (Peterlin and Price, 2006). 
Flavopiridol, which inhibits PTEF-b, prevents RNA polymerase II from processive 
elongation in vivo (Ni et al., 2008). P-TEFb inhibition by flavopiridol blocked the pause-
release in many genes in human embryonic stem cells (Rahl et al., 2010), and it 
demonstrates the effect of these factors and their interactions. 
There are some characteristics in common among the genes with transcriptional 
pause. Genes related to signal transduction pathways, development, proliferation, and 
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stress response were found to be enriched among the genes with RNA polymerase II 
pausing (Adelman and Lis, 2012). 
The pluripotency genes in human embryonic stem cells are regulated through 
trancriptional pause release, and P-TEFb and CDK9 have a role in the activation of 
these genes in reprogramming, thereby causing changes in development (Liu et al., 
2014). The transcriptional pausing at the promoter-proximal regions of several genes is 
important in proliferation and stress response, because some of these factors 
themselves, such as the c-Myc, HSF, p53, and NF-κB, can contact P-TEFb and make it 
activate gene expression (McNamara et al., 2016). Among these transcription factors, 
the role of c-Myc in the transcriptional pause release is evident in human embryonic 
stem cells, as c-Myc binds to P-TEFb, and the knockdown of c-Myc caused increased 
pausing in these cells (Rahl et al., 2010). 
This gives clues and raises questions about the possibility of the transcriptional 
pausing as a method of diversifying the transcriptome and proteome upon various 
environmental stresses. Genotoxic stress, which can impact transcriptional output, as 
well as the transcriptional stress itself, can affect RNA polymerase II pausing, which is 
likely to cause changes in alternative splicing. 
1.3.3 Alternative splicing upon transcriptional stress 
The coupling between transcription and splicing, and its effect on the splicing of several 
genes raised questions about whether there are alternatively spliced stress- or 
proliferation-associated transcripts that affect proliferation or the overall metabolic 
phenotype. The transcriptional stress induced by different means leads to similar global 
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outputs of alternative splicing, and the subset of transcripts that are sensitive to DRB 
also respond to UV exposure (Ip et al., 2011).  
Fibronectin EDI exon is among the well-studied exons that respond to the 
transcriptional stress in several cell types. DRB-induced transcription inhibition caused a 
2-fold increase in EDI inclusion in Hep3B cells (Nogués et al., 2002). The same exon 
responded similarly to low-dose UVC and cisplatin treatment in Hep3B cells, along with 
the increase in the proapoptotic spliced isoforms of two transcripts, Bcl-x and caspase 9 
(Muñoz et al., 2009). Different promoters may also have different effects on the splicing 
of EDI, and its inclusion is higher in wound healing and proliferating tissues. 
P-TEFb can either be in its active form, that causes release of the paused RNA 
polymerase, or the inactive form that is bound by the 7SK noncoding RNA complex in 
the cell. The SR family members SRSF1 and SRSF2 were found to be part of the 7SK 
noncoding RNA complex and connect P-TEFb to RNA polymerase II (Ji et al., 2013). 
Several hnRNP family members also bind the 7SK noncoding RNA, which increases the 
possibility of transcriptional stress and pausing to have an effect on the alternative 
splicing of the transcripts under the control of these splicing factors (Ji et al., 2013). 
Faster and slower transcriptional rates cause changes in the splicing of different 
genes. A subset of exons were documented to have increased inclusion upon slower 
RNA polymerase II transcription rates, and some of the exons are increasingly skipped 
upon transcriptional inhibition or in slower RNA polymerase II mutant strains (Fong et 
al., 2014). The subset of exons with increased skipping upon DRB treatment were 
observed to be enriched in AT-rich sequences in their flanking introns, but there is also 
an enrichment of GU-rich sequences in the transcripts with higher exon inclusion upon 
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DRB treatment (Fong et al., 2014). This model does not seem to be consistent, because 
there are exons with alternative splicing patterns that do not follow AT or GU 
enrichment. There are exons that do not respond to slow or fast transcription elongation 
rates. However, optimal transcription rate is needed for transcripts to have enough time 
for spliceosome assembly and splicing factor recruitment (Fong et al., 2014). 
Splicing is under tissue-specific and developmental regulation, and some of the 
slow-included or fast-included exons can have alternative splicing patterns that are 
correlated with the proliferative phenotype of the cell. The abundance and localization of 
splicing factors in the cell can also affect the splicing response to the changes in the 
rate of transcription.  
Different signaling pathways that affect the proliferation of the cell also affect the 
rate of transcription. TNF-α and NF-κB were suggested to increase RNA polymerase II 
elongation at sites of transcriptional pausing among the target genes of this pathway, as 
a possible way of regulating the fate of their target transcripts (Danko et al., 2013). The 
signaling pathways that affect transcription rates can be a way of adjusting the splicing, 
due to the spatial and temporal coupling between splicing and transcription in the cell. 
The knockdown of the SR-family splicing factor SC35 was shown to cause 
abortive transcription elongation, providing a possible effect of splicing factors on the 
rate and processivity of transcription (Lin et al., 2008). The effect of hnRNP A1/A2 
knockdown and the effect of DRB-induced transcriptional inhibition were suggested to 
lead to similar results on gene transcription, due to a partial overlap in the repression of 
a similar set of transcripts (Lemieux et al., 2015). 
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In the light of the findings related to genotoxic and transcriptional stress on the 
mRNA splicing, it is possible to speculate that the effect will be context- and sequence-
dependent, and it can be controlled or regulated by different signaling pathways. 
1.4 HNRNPH1 AND HNRNPH3: HNRNP H-ENCODING GENES 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a class of proteins that 
are mostly localized in the nucleus, some of which are also present in the cytoplasm. 
They are among the proteins with highest abundance in the cell, and there are many 
different types of hnRNPs in mammalian cells (Choi et al., 1986). HnRNPs bind to RNA 
via RNA recognition motifs (RRMs), and this binding is sequence-specific, although the 
RNA motifs that are capable of binding to these RNA recognition motifs do not require a 
very strict sequence. The promiscuity of RRM and RNA motif binding is important, 
because one RNA motif can be bound by multiple hnRNPs or other splicing factors. 
HnRNPs can have context-dependent effects on splicing, which vary due to the 
magnitude of the binding affinity and the location of the RNA motif with respect to the 
intron and exon. HnRNPs can usually act as splicing repressors by binding to silencer 
RNA motifs and preventing the spliceosome assembly, and they have additional 
functions such as protecting mRNAs from degradation, shuttling between nucleus and 
cytoplasm, and modulating transcript stability (Dreyfuss et al., 1993). Thus, hnRNPs are 
worth investigating in detail, due to their several duties and effects on the transcriptome. 
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1.4.1 HnRNP H family of splicing factors and their target transcripts 
HnRNP H belongs to a family of splicing factors that also contain the closely related but 
separate protein hnRNP F, both of which have ubiquitous expression in cells (Bent et 
al., 1995). HnRNP H family consists of hnRNP H1, hnRNP H2 (H’), hnRNP H3 (2H9), 
and the hnRNP F (Caputi and Zahler, 2001). HnRNP H uses three glycine-rich highly-
conserved quasi-RRMs (qRRMs) for binding RNA, and interacts with poly(G) stretches 
to affect splicing in a context-dependent manner (Dominguez et al., 2006). HnRNP H 
was shown to bind to GGGA, and is also required for the interaction of U1 snRNP with 
the enhancer in HIV-1 tev-specific exon 6D (Caputi and Zahler, 2002). 
HnRNP H family members are important in the coupling between transcription 
and splicing. For instance, hnRNP F interacts with the TATA-binding protein (TBP) and 
the C-terminal domain (CTD) of the RNA polymerase II (Yoshida et al., 1999). The CTD 
can be used as a landing pad by the splicing factors to be transferred onto the newly 
emerging nascent transcript, in order to perform their functions in splicing. 
HnRNP H is implicated in a number of diseases, especially in different cancers. 
HnRNP H is overexpressed in pancreatic, hepatocellular, and gastric carcinomas, with 
an increase in the cell nucleus in these cancer types (Honoré et al., 2004). In gliomas, 
hnRNP H levels are increased, and this upregulation is involved in a shift to more 
malignant and aggressive phenotype (LeFave et al., 2011). HnRNP H1 has an effect on 
the splicing of HER2 in breast cancer cells, and HER2 is a special gene that is present 
in HER2-positive breast cancer (Gautrey et al., 2015). 
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HnRNP H and hnRNP F bind to G-rich sequence motifs for exerting their effect 
on splicing, which usually act as splicing repressors. HnRNP H2 and hnRNP F were 
previously shown to bind to similar sequences, albeit in different ways, to affect gene 
expression (Alkan et al., 2006). HnRNP F was shown to bind only to the single-stranded 
G stretches, and this binding was proposed to obstruct the formation of G-quadruplex 
structures (Samatanga et al., 2012). Poly(G) stretches, especially the GGGG motifs act 
as silencers, and they are bound by hnRNP H and hnRNP F (Sohail et al., 2014). In a 
global analysis of splicing, the poly(G) stretches were found to favor exon skipping, and 
the binding of hnRNP H required a continuous G stretch (Rahman et al., 2015). 
The effect of hnRNP H on the splicing of proliferation-associated transcripts is 
important, due to its effect on the several important genes related to apoptosis. Bcl-x is 
one of the most well-known apoptosis-related genes, and hnRNP H causes the splicing 
of Bcl-x to favor the pro-apoptotic Bcl-xS, rather than the anti-apoptotic Bcl-xL, in HeLa 
cells (Garneau et al., 2005). The 30-nucleotide G-rich stretch located in the Bcl-x was 
shown to be important in the response of Bcl-x splicing to the Protein Kinase C (PKC) 
inhibitor Ro, giving rise to a pro-apoptotic phenotype upon Ro treatment (Hai et al., 
2008). On the other hand, hnRNP H also has an anti-apoptotic effect on the MAP 
kinase pathway, by causing an increase in the A-Raf (Rauch et al., 2010). This 
regulatory mechanism can be a fine-tuning response of multiple inputs, and it can affect 
the proliferation versus apoptosis decision of the cells upon different signals and 
environmental conditions. 
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1.4.2 Alternative splicing of HNRNPH1 and HNRNPH3 transcripts 
HnRNP H proteins are encoded by HNRNPH1, HNRNPH2, and HNRNPH3 paralogous 
genes in human (Flicek et al., 2012). Their mouse orthologs are Hnrnph1, Hnrnph2, and 
Hnrnph3 respectively. It is a very highly-conserved family, with orthologs in various 
organisms ranging from different fish species to fruitfly, dolphin to xenopus, sheep to 
cat. Their conservation is an obvious sign of crucial functions for their protein products, 
and the similarities of the alternative splicing patterns across orthologs and paralogs 
provide hints about possible gene duplication events in the evolution of this gene family. 
HNRNPH1 and HNRNPH3 paralogous transcripts, which share easily-identifiable 
characteristics, have several different 5’ and 3’ untranslated regions (UTR) with varying 
lengths, suggesting tissue-specific regulation of their protein products depending on the 
needs of different types of cells. The arrangement of their exons has some similarities, 
encompassing a 139-base pair cassette exon (HNRNPH1 Exon 4 and HNRNPH3 Exon 
3) with a high conservation and sequence identity (Grabowski, 2004). 
The alternatively-spliced HNRNPH1 E4 and HNRNPH3 E3 cassettes correspond 
to parts of the RNA recognition motif domain in the hnRNP H1 and hnRNP H3 protein 
products, and they seem to be skipped in the non-coding transcripts, which undergo 
nonsense-mediated decay across several human and mouse orthologs. Interestingly, 
these alternatively-spliced cassette exons share a guanine stretch in the immediately 
downstream flanking intron (Grabowski, 2004), and this common putative cis regulatory 
RNA motif is bound by the hnRNP H protein (Stein, 2015). The direct binding between 
the transcript and its protein product suggests an autoregulatory loop, affecting the fate 
of the alternative splicing of its own transcript. 
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The presence of the GGGG motif in the immediately downstream flanking intron 
is a characteristic that was previously identified as part of a splicing code, found in a 
genomewide search for a common combination of exonic UAGG and intronic GGGG 
(Han et al., 2005). This splicing code was initially identified in the NMDA R1 receptor-
encoding GRIN1, a neuronal transcript explained in the next section. 
1.5 NMDA R1 RECEPTOR AND THE GRIN1 GENE 
1.5.1 The biology of NMDA R1 receptor and GRIN1 splicing 
The NMDA (N-methyl-D-aspartate)-type receptors are glutamate-gated Ca2+ channels 
found in mammals, and they have many different functions in the strength of synapses, 
sensitivity of the postsynaptic membranes, and neuronal cell death in some instances 
(Aoki et al., 1994). These receptors mediate the flow of calcium ions, and the calcium is 
involved in several signaling pathways in the cell, leading to synaptic plasticity within the 
context of memory and learning (Traynelis et al., 2010). 
NMDA receptors are shown to affect the synaptic connectivity, learning from the 
environmental experiences, action selection, and behavior (Lambot et al., 2016). They 
were recently shown to promote the survival of neurons in cochlea (Zhang-Hooks et al., 
2016). The location-dependent effects of the NMDA receptors depend on where they 
are expressed in the brain. 
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 NMDA receptors have multiple subunits, belonging to the R1, R2 or R3 classes 
of receptors, and each subunit has several alternatively-spliced isoforms (Cull-Candy et 
al., 2001). The R1 receptor expression is low in several rat brain regions at birth, and its 
levels increase after three weeks (Luo et al., 1996). Different NMDA receptor variants 
arise due to alternative splicing, and they have different functions as a result of diverse 
structures (Nakanishi et al., 1992). Therefore, the alternative splicing of NMDA receptor 
subtypes contribute to the neuronal plasticity, diversity and functions in different regions 
of the brain. The alternative splicing can rapidly change upon changing environmental 
conditions, which is possibly a strategy for the brain to adapt during learning. 
1.5.2 Alternative splicing of GRIN1 in different brain regions 
GRIN1 has three alternatively spliced exons that give rise to eight isoforms, and these 
isoforms have different functions (Zukin and Bennett, 1995). The NI and CI cassette 
exons of the GRIN1 transcript, both of which are alternatively spliced, encode part of the 
extracellular and intracellular domains of the receptor respectively (Bradley et al., 2006), 
and function in the sensitivity and the localization of the receptor (Ehlers et al., 1995; 
Okabe et al., 1999). Alternative splicing appears as a strategy to adjust the function and 
location of the receptor, adapting to different conditions. 
 The splicing of NI and CI are controlled by the brain region-specific CUGBP2 (or 
NAPOR), which was shown to cause CI inclusion and NI skipping in the forebrain, and 
with the exact opposite effect due to the absence of CUGBP2 in the hindbrain (Zhang et 
al., 2002). The compartmentalization of the different versions of NMDA R1 receptor is 
important, as the extracellular domain partially encoded by NI plays a role in adjusting 
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the sensitivity of the receptor to different ions, and the CI-encoded intracellular domain 
is involved in the membrane localization and intracellular signaling (Cull-Candy et al., 
2001). The CI exon is particularly important, due to the presence of a GGGG motif that 
is present in the flanking intron immediately downstream of the exon (Han et al., 2005). 
 The splicing of CI cassette exon is controlled by the splicing enhancer sequences 
for the binding of ASF/SF2, SC35, and SRp40 within the exon, and the intronic sites for 
hnRNP H and NAPOR/CUGBP2, with the presence of two exonic UAGG motifs and an 
intronic GGGG motif (Han et al., 2005). Both the intronic and exonic RNA motifs, along 
with the splicing factors binding to these motifs, contribute to the regulation of the CI 
splicing, fine-tuning the inclusion and skipping. The GRIN1 splicing represents a good 
example of an orchestrated regulation by different splicing factors, adjusting the activity 
of the NMDA receptor in a tissue-specific and developmentally-specific manner (Black 
and Grabowski, 2003). 
1.5.3 Alternative splicing of GRIN1 upon neuronal excitation 
The splicing of CI is inducible by potassium chloride (KCl) excitation, giving rise to exon 
skipping upon depolarization, and the splicing is reversed to the steady-state levels 
upon the removal of KCl (An and Grabowski, 2007), suggesting an adjustable splicing 
regulation that responds to the voltage changes across the membrane and neuronal 
impulses. CI encodes an intracellular region of the NMDA R1 receptor; therefore the 
NMDA receptor agonists and intracellular signal transduction inhibitors (such as the 
Protein Kinase A) cause a decrease in the responsiveness of the alternative splicing to 
neuronal excitation, and the hnRNP A1 is the splicing factor that acts to increase the 
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sensitivity to neuronal depolarization (An and Grabowski, 2007). Therefore, it can be 
suggested that the alternative splicing of the CI can be influenced by the signaling 
pathways, contributing to or countering the effect of membrane voltage changes. 
 The splicing of GRIN1 CI cassette exon is responsive to KCl excitation of the rat 
cortical neurons, and the binding of hnRNP A1 to UAGG motifs was demonstrated to 
increase upon neuronal depolarization (An and Grabowski, 2007). Since the hnRNP A1-
binding UAGG was part of the UAGG-GGGG splicing code influencing the CI splicing, 
the hnRNP H family members that bind to the GGGG motif are also of special interest. 
The binding of hnRNP H to the GGGG motif of its own transcript, taken together with 
the regulation of GRIN1 splicing by hnRNP A1 and hnRNP H, suggests a regulation of 
HNRNPH1 and HNRNPH3 splicing by their own protein products and different types of 
cellular stresses, possibly interfering with the binding of hnRNP H to the GGGG motif 
and the binding of hnRNP A1 to the UAGG motif. 
1.6 THESIS GOAL AND OBJECTIVES 
By describing the current knowledge about the alternative splicing of several exons with 
respect to cellular stresses and diseases, I provided the framework of this study, which 
aims to address different gaps and questions that are interrelated with each other. The 
questions involve the modulating and fine-tuning role of hnRNP H on splicing upon 
transcriptional stress and pause-release, the role of hnRNP H possibly as an adaptation 
mechanism for the cell to handle the changing conditions and give a splicing response 
to the intracellular and extracellular challenges that affect mRNA transcription. The 
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results shed light on the role of cis regulatory RNA elements and trans-acting splicing 
factors involved in the splicing response to stress. 
How does hnRNP H act in response to the genotoxic and transcriptional stress, 
and is this alternative splicing regulation reversible upon transcriptional pause-release, 
possibly in relation to the tissue-specific and developmental regulation? Is the splicing of 
hnRNP H-encoding transcript subject to autoregulation? Can GRIN1, the previously-
characterized transcript with an inducible splicing pattern upon depolarization, act as a 
model for the alternative splicing regulation upon transcriptional stress? Is the splicing 
response to transcriptional stress specifically regulated by a predicted splicing code? 
 In light of these questions, the specific goals of this study are as follows: 
1- Determining the effect of genotoxic and transcriptional stress on the splicing of the 
previously predicted hnRNP H-encoding HNRNPH1 and HNRNPH3, sharing a UAGG-
GGGG predicted splicing code 
2- Establishing an RNA map to understand the cis-regulatory elements and trans-acting 
splicing factors on the splicing of conserved HNRNPH1 exon 4 and HNRNPH3 exon 3 
3- Investigating the mechanism of alternative splicing upon transcriptional pausing and 
pause-release in the cloned rat GRIN1 CI reporter minigene and a set of mutants 
 Our main question is to understand the role of hnRNP H in the splicing response 
to genotoxic and transcriptional stress. The previous work on the HNRNPH1 exon 4 and 
HNRNPH3 exon 3 involved their fast response to the KCl excitation in neurons (An and 
Grabowski, 2007). Cancer cells are subject to many different types of stress including 
genotoxic and transcriptional stress, and splicing is possibly one of the ways to adapt to 
the rapidly changing environment. Transcriptional pausing is observed in many genes of 
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embryonic stem cells, hinting at a temporal regulation of splicing in development. I 
hypothesize that the hnRNP H has a role in fine-tuning splicing upon genotoxic and 
transcriptional stress, through the previously predicted UAGG-GGGG splicing code. 
The previously-characterized combinatorial roles of hnRNP A1 and hnRNP H on 
the splicing of GRIN1 and the prediction of HNRNPH1 and HNRNPH3 in a genomewide 
search for the UAGG-GGGG splicing code (Han et al., 2005) constitutes a foundation 
for a possible role of these splicing factors on the alternative splicing of the hnRNP H-
encoding transcripts, which share the same splicing code. The different exons such as 
Bcl-x that are responsive to different cellular stresses, and the role of hnRNP H in the 
regulation of the exons (such as Bcl-x) that carries poly(G) stretches, suggest a role for 
the hnRNP H in the splicing of its own transcript and in the response to cellular stresses 
as a fast and reversible way of modulating and fine-tuning the stress response. 
In order to analyze the splicing of HNRNPH1 exon 4 and HNRNPH3 exon 3, the 
percentages of exon inclusion upon genotoxic and transcriptional stress-inducer small 
molecules were determined. Bioinformatics tools were utilized to establish an RNA map 
of cis-regulatory elements. The reporter-cloned rat GRIN1 minigene, that shares the 
common UAGG-GGGG splicing code, was used as a model to understand the motifs 
that regulate the effect of transcriptional stress on splicing. The set of mutants, in 
comparison with the wild type, were transfected to observe the same treatments and 
their outcome. HeLa cells were used as a model system due to very high transfection 
efficiency, easy propagation and application of stress inducers, and wide use. 
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Understanding the role of the hnRNP H in the fine-tuning of alternative splicing 
upon transcriptional stress is one of the main steps required to elucidate a bigger 
cellular stress-response pathway, involving crucial steps of alternative splicing. 
 30 
2.0  MATERIALS AND METHODS 
2.1 PLASMID CONSTRUCTS AND PCR PRIMER DESIGN 
All of the GRIN1 C1 cassette exon 5’ splice site mutants used in this study were the 
derivatives of the wild type Exon 21 splicing reporter E21wt (Zhang et al., 2002) in the 
pBPSV pA+ vector (Nasim et al., 1990), as previously described (Han et al., 2005). Rat 
GRIN1 transcript-203 sequence was obtained from Ensembl Genome Browser. GRIN1 
E18/E20 fragment was previously cloned by Dr. Kyoung Han into the pBPSV pA+ with 
XbaI and EcoRI (Han et al., 2005). The pA+ C1 cassette splicing reporters; wild-type 
C1wt0, UAGG mutant E17, UAGG-GGGG mutant T8, and the GGGG mutants 5m2 and 
5m4 were the same as described (Han et al., 2005; An and Grabowski 2007). Human 
HNRNPH1 transcript-001, human HNRNPH3 transcript-012, mouse Hnrnph3 transcript-
001 sequences were obtained from Ensembl Genome Browser. HnRNP A1 expression 
plasmid was the derivative of the pcDNA4/HisMax, as described (Han et al., 2005). The 
PKA expression plasmid was a gift from Dr. Jiuyong Xie (University of Manitoba). 
The specific forward and reverse PCR primers that amplify the HNRNPH1 E3/E5, 
human HNRNPH3 E2/E4, mouse Hnrnph3 E2/E4 (Table 1) were designed within exons, 
BLAST-checked and optimized by using IDT Oligo Analyzer. H3E3 Forward primer was 
also used in the TAMRA-fluorolabeled form, and the PCR products were visualized with 
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the ImageGauge using the 540/575 nm (excitation/emission) wavelengths to confirm the 
splicing changes without gel background or other impurities interfering with the image. 
The sequences of HNRNPH1 and HNRNPH3 primers are: 
H1E4 Forward: 5’ TTGGGTGTTGAAGCATACTGG 3’ 
H1E4 Reverse: 5’ CATAAGCTTTCGTGGTGGATCA 3’ 
H3E3 Forward: 5’ AATGGTCCAAATGACGCTAG 3’ 
H3E3 Reverse: 5’ CCAGCAATCTTCTTGGTGG 3’ 
 The specific forward and reverse PCR primers to amplify the GRIN1 C1 cassette 
exon were used, as described (Han et al., 2005). Their sequences are: 
NMDA3021: 5’ ATGCCCGTAGGAAGCAGATGC 3’ 
NMDA3255A: 5’ CGTCGCGGCAGCACTGTGTC 3’ 
The specific forward and reverse primers for the control PCR that amplify the 
beta actin (ACTB) E1/E3 and were designed within the exonic regions, BLAST-checked 
and optimized by using IDT Oligo Analyzer. Their sequences are: 
ACTB Forward: 5’ AGCTTCTTTGCAGCTCCTTC 3’ 
ACTB Reverse: 5’ TCTTCTCCATGTCGTCCCAG 3’ 
2.2 SPLICING FACTOR PREDICTIONS AND THE RNA MAPS 
Based on the sequences obtained from Ensembl genome browser, the Human Splicing 
Finder (HSF) online tool (http://www.umd.be/HSF3/) and the Exonic Splicing Enhancer 
Finder (ESEfinder) online tool (http://rulai.cshl.edu/tools/ESE/) were used to construct 
the RNA maps, including the scores for each predicted RNA motif represented by a 
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probability score to bind a particular splicing factor (Tables 2-8). Scores higher than 80 
percent were highlighted as bold characters. 
Rat GRIN1 CI cassette exon RNA maps, previously described (Han et al., 2005), 
were updated and adapted according to the predictions from HSF and ESEfinder online 
tools. HNRNPH1 E4 and HNRNPH3 E3 RNA maps were prepared, according to the 
CLUSTALW multiple sequence alignment, provided online on EMBL-EBI CLUSTALW2 
page: (http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
2.3 RNA PREPARATION FROM TISSUES AND CULTURED CELLS 
Cryofrozen mouse brain and liver samples were gifts from Dr. James Pipas (University 
of Pittsburgh). The samples were thawed on ice, in order to minimize RNA degradation. 
Each tissue sample was weighed, using clean 15 mL tubes. 3 mL Trizol (Ambion Life 
Technologies) was added on the tissues, and the tissues were homogenized by dounce 
homogenizer. Total RNA was extracted from the homogenates via phenol-chloroform 
RNA extraction, according to the manufacturer’s protocol. 
After the transfection or treatment, 500 µl Trizol (Ambion Life Technologies) per 
well were used for extracting RNA from cultured HeLa CCL-2 or U2OS cells via phenol-
chloroform total RNA extraction, according to the manufacturer’s protocol. 
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2.4 CULTURING AND TRANSFECTION OF THE HELA CCL-2 CELLS 
HeLa CCL-2 cells were grown in Dulbecco’s Modified Eagle Medium DMEM (Cellgro) 
supplemented with heat-inactivated 10% (v/v) fetal bovine serum (FBS), inside a sterile 
37°C incubator with 5% CO2. 24 hours before the transfection or treatment, the cells 
were splitted to six-well plates to achieve 70% confluency. 
For transient transfection, 500 ng pcDNA4-hnRNP A1, pcDNA4-PKA or pcDNA4 
were used, along with 125 ng pA+-C1wt0, pA+-5m2 or pA+-5m4, per well. The plasmids 
were mixed with 100 µl OptiMEM (Gibco) per well, and mixed to equal volume of 
OptiMEM that has 2 µl lipofectamine 2000 (Invitrogen) per well. The transfection mixture 
was incubated at room temperature for 20 minutes. The DMEM + 10% FBS on the cells 
was removed, and 1 mL OptiMEM was added before transfection. 
For checking the transfection efficiency, the cells were seeded on six-well plates 
that have cover slips. The following day, the EYFP-A1 plasmid was also transfected, 
and the EYFP+ cells on the cover slips were mounted on slides and they were observed 
under the microscope to estimate the percentage of transfection, which was determined 
as 70 percent, by checking the ratio of EYFP+ nuclei to DAPI-stained cell population. 
2.5 HNRNP A1 OVEREXPRESSION AND HNRNP A1/H KNOCKDOWN 
In order to knock down the hnRNP A1 and hnRNP H, HeLa CCL-2 cells were seeded 
on a six-well plate 24 hours prior to the transfection. The confirmed siRNAs targeting 
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the hnRNP A1/A2 and hnRNP H, namely the siA1/A2 and siH, were transfected into the 
cells. HeLa CCL-2 samples overexpressing hnRNP A1 were prepared by Dr. Ping An. 
2.6 GAMMA IR AND CISPLATIN-INDUCED DNA DAMAGE  
The U2OS human osteosarcoma cells were grown in triplicates on the 60 mm plates 
overnight, and they were treated with 2.8-3 Gy of γ-radiation by exposing them to 137Cs 
for 15 minutes. Following the γ-IR treatment, the cells were either harvested right after 
the irradiation (0h post-IR), or allowed to recover until the 8h, 18h and 24h time points. 
Double-stranded DNA damage was confirmed by Western Blot against phosphohistone 
Ser139 γ-H2AX (Figure 5). 
The HeLa CCL-2 (ATCC) cells were splitted to six-well plates the day before the 
treatment, and grown overnight. They were treated with the 0-20-40 μM cisplatin, by 
preparing the mixture of 0.9% autoclave-sterilized NaCl with a main stock of 50 mM 
cisplatin (Sigma) and diluting the main stock in fresh DMEM + 10% FBS. The control 
cells were treated with the medium including equal volume of 0.9% NaCl. The treated 
and control cells were harvested after the 14-hour cisplatin treatment. 
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2.7 DRB TREATMENT AND TRANSCRIPTIONAL PAUSE-RELEASE 
The HeLa CCL-2 cells, seeded on six-well plates 24 hours prior to treatment with or 
without lipofectamine transfection, were grown inside a sterile 37°C incubator in the 
presence of 5% CO2, in DMEM+10% FBS. If the cells were not transfected, they were 
treated with 0-30-40 μM DRB. The DRB stock solution was 50 mM, which was prepared 
in sterile 95% ethanol. The dilutions were prepared from the 50 mM stock in the sterile 
DMEM+10% FBS, and this mixture was used to replace the growth medium of the cells. 
If the cells were transfected and then treated with DRB, they were grown in six-
well plates overnight, as previously explained in 2.4. The cells were transfected with the 
lipofectamine mixture, with the presence of the OptiMEM instead of DMEM+10% FBS. 4 
hours after the transfection, the OptiMEM was removed and replaced by the DRB mix 
that was diluted in fresh sterile DMEM+10% FBS. The cells were incubated for 14 hours 
inside a sterile 37°C incubator in the presence of 5% CO2. 
For the transcriptional pause-release, the cells were washed once with the fresh 
DMEM+10% FBS following the 14-hour DRB treatment, and were incubated in the fresh 
DMEM+10% FBS for 30 minutes, 1 hour, and 2 hours. If the cells were harvested at the 
0-hour time point, they were immediately harvested following the DMEM+10% FBS 
wash, without further incubating inside a sterile 37°C incubator. 
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2.8 LYSATE PREPARATION, SDS-PAGE AND WESTERN BLOTTING 
Total cell lysates of HeLa CCL-2 cells were prepared from each well of the six-well plate 
and two wells with the same treatment were combined to obtain one 1.5 mL tube of total 
cell lysate. The cells were harvested in the +4°C cold room and on ice to minimize the 
protein degradation due to temperature increase. The cells were harvested by adding 
75 μl ice-cold RIPA buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% 
sodium deoxycholate, 0.1% SDS, 1% Triton X-100) per well. The cells were scraped off 
the plate by the use of a rubber scraper and transferred into a 1.5 mL Eppendorf tube 
prechilled on ice. The duplicate wells having the same content were combined to obtain 
a final volume of 150 μl. The lysate was sonicated for 10 seconds on setting 3, and 
aliquotted into single-use 20 μl aliquots for flash-freeze in dry ice, and stored at -80°C. 
The whole cell lysates were used for SDS-PAGE and Western blot analysis. The 
whole cell lysates, prepared as mentioned above, consisted of the cells scraped in RIPA 
buffer, sonicated and aliquoted. The concentrations of the whole cell lysates were not 
measured due to the presence of SDS. The SDS-PAGE was performed with the BioRad 
12% precast acrylamide gels. The SDS-PAGE protein samples were prepared by cold 
centrifugation of the cell debris at +4°C at the 10,000 rpm speed for 5 minutes. After the 
spin, the supernatant was transferred into a prechilled ice-cold clean 1.5 mL eppendorf 
tube. 6X SDS loading buffer (1 M Tris-HCl pH 6.8, 30% glycerol, 10% SDS, 600 mM 
DTT, 0.012% bromophenol blue) was added to obtain a final concentration of 1X. 
The 1X samples that include the SDS loading dye were boiled on the 100°C heat 
block for 10 minutes. The acrylamide gel was placed in BioRad MiniProtean acrylamide 
electrophoresis reservoir, and 15 μl of each 1X sample was loaded on the gel. The gel 
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was run in 700 mL of 1X SDS-PAGE Running Buffer (50 mM Tris-HCl, 400 mM glycine, 
0.1% SDS) under 90V for 80 minutes, until the bromophenol blue dye band reached the 
bottom of the reservoir. 
The gels were equilibrated in the 1X Transfer Buffer (25 mM Tris-HCl, 192 mM 
glycine, 20% methanol) for 15 minutes, and then sandwiched with the Immobilon-PSQ 
hydrophobic 0.2 μm PVDF membrane by wetting the membrane with absolute methanol 
before use. The sandwiched pad-gel-membrane-pad was completely soaked in the 1x 
Transfer Buffer, and the bubbles were removed with the help of a glass Pasteur pipette 
by rolling several times. The sandwiched pad-gel-membrane-pad was located into the 
color-coded plastic BioRad MiniProtean Tetra Cell cassette, inserted into the BioRad 
MiniProtean Tetra Cell transfer tank, and transferred under 120V for 75 minutes in the 
+4°C cold room in order to minimize overheating and potential hazards, according to the 
manufacturer’s protocol. 
For the Western blot analysis, the PVDF membrane with the transferred proteins 
was blocked in 5% non-fat milk powder dissolved in PBST (1X phosphate buffer saline 
[PBS], 0.1% Tween-20) for 1 hour at room temperature on the shaker while shaking at 
60 rpm, followed by a 5-minute wash in 1X PBST. The PVDF membranes were marked 
with a small letter to label the type of antibody used and to recognize the surface that 
has the transferred proteins. 
The membranes were incubated with the primary antibody for at least 1 hour (up 
to overnight, depending on the antibody) in the +4°C cold room, while rotating at 60 
rpm. The primary antibodies were diluted in pre-chilled ice-cold 1X PBST + 1% BSA as 
follows: α-Beta Tubulin (1:200), α-hnRNP H (1:250), α-Phospho-Histone H2AX [Ser139] 
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(1:500), α-HA (1:250), α-ASF (1:500), α-SC35 (1:1,000). The membranes were washed 
four times, 10 minutes each, with 1X PBST at room temperature, to wash the unbound 
antibodies, following the primary antibody incubations. After the four washes, the PVDF 
membranes were incubated with the mouse, rabbit, or goat HRP-conjugated secondary 
antibodies, which were diluted 1:20,000 in the pre-chilled ice-cold 1X PBST + 1% BSA, 
while rotating in the +4°C cold room at 60 rpm for 1 hour. After the secondary antibody 
incubations, the membranes were washed four times, 10 minutes each, with 1X PBST 
at room temperature, to wash the unbound antibodies. 
After the end of the washes, the membranes were treated with equal volumes of 
Perkin Elmer Western Lighting Chemiluminescence Plus Enhanced Luminol Reagent 
and Oxidizing Reagent for 3 minutes before developing the chemiluminescence signal 
images with the LAS-3000 FujiFilm Intelligent Dark Box by using 15-second increments 
of exposures for optimization, and the chemiluminescence images were then analyzed 
with the ImageReader, ImageGauge, and ImageJ softwares. 
2.9 SPLICING ANALYSES: RT-PCR AND THE ELECTROPHORETIC BAND 
QUANTIFICATIONS 
Total RNA was extracted from the HeLa CCL-2 cells, as described in 2.3, according to 
the manufacturer’s protocol. After the phenol-chloroform RNA extraction, the total RNA 
concentration was measured by NanoDrop 2000, and diluted to 1 μg/μl in RNase-free 
sterile dH2O. The total RNA was reverse transcribed with the Invitrogen SuperScript III 
Reverse Transcriptase enzyme in a reaction containing 2 μg of total RNA, 1 μl random 
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hexamer primers (Promega), 0.5 mM dNTPs, 10 mM DTT, 1X First Strand (FS) Buffer 
(50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2) and 200 U Invitrogen SuperScript III 
Reverse Transcriptase in a final volume of 20 μl. 
The primer-template mixture was denatured at 70°C for 10 minutes, annealed at 
room temperature for 10 minutes, and the reverse transcription reaction was carried out 
in the thermocycler at 50°C for 1 hour. Finally, the reverse transcription reaction was 
stopped by heat inactivation at 65°C for 15 minutes, according to the manufacturer’s 
protocol. 
Polymerase chain reaction (PCR) was performed at a volume of 10 μl each, that 
has 1 μl of the heat-inactivated reverse transcription reaction, 2 μl of 5X GoTaq Green 
Buffer (Mg2+ already optimized) to make a final concentration of 1X, 2.5 U of GoTaq Taq 
DNA polymerase (Promega), 0.2mM dNTPs, and 0.1 μM of each of the exon-specific 
forward and reverse primers that were diluted in nuclease-free dH2O to a stock solution 
of 20 mM. The PCR steps and conditions were optimized as follows: 
Initial denaturation at 94°C for 2 minutes; followed by 26 cycles of denaturation at 
94°C for 30 seconds, annealing at 60°C for 30 seconds, and elongation at 72°C for 45 
seconds (1 kb/min). Final elongation was performed at 72°C for 10 minutes, and the 
products were cooled to +4°C, flash frozen with dry ice and stored at -80°C. 
PCR products were resolved on 1.8% agarose gel, prepared with 1.8 grams of 
ultrapure agarose, 100 ml 1X TBE (89 mM Tris Borate pH 8.3 + 2 mM Na2EDTA) diluted 
from 10X stock with Nano-pure dH2O, and 1 μl EtBr from a stock solution of 10 mg/ml. 
The agarose gels were run under 110V for 80 minutes, and the DNA ladder used in first 
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wells was 1 μl 1-kb Plus DNA ladder (Invitrogen). The gels were autoexposed with the 
FujiFilm LAS-3000 Intelligent Dark Box, analyzed with ImageReader and ImageGauge. 
Electrophoretic band intensities were measured by ImageGauge, by selecting a 
rectangular region encompassing each well of the gel, subtracting the background from 
the peaks in the analysis curves of the software, in the Profile/MW setting. The graphed 
values show percent inclusion and skipping, and error bars show standard deviation. 
The changes in splicing were calculated as a difference of the percentages of 
exon inclusion, which was denoted as the Ψ (PSI = Percent Spliced In) value, and it 
was calculated by subtracting the exon inclusion of the control group from the exon 
inclusion of the experimental group to obtain the ΔΨ (Wang and Burge, 2008). For the 
statistical analysis, the student’s t test was used, with p-value < 0.05 at a confidence 
interval of 95%. Analyses were performed with Microsoft Office 2010 Excel in triplicates. 
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3.0  RESULTS 
3.1 HNRNPH1 EXON 4 AND HNRNPH3 EXON 3 RESPOND SIMILARLY TO 
SINGLE-STRAND GENOTOXIC AND TRANSCRIPTIONAL STRESS 
3.1.1 Introduction 
HnRNP H family of splicing factors are encoded by the human HNRNPH1, HNRNPH2, 
and HNRNPH3 transcripts; two of which are alternatively spliced: HNRNPH1 and 
HNRNPH3. These transcripts were previously found in a genomewide search to have a 
common UAGG-GGGG splicing code with the brain region-specific GRIN1 CI cassette 
exon (Han et al., 2005). Different proliferation-associated exons, such as the Fibronectin 
EDI exon, were previously studied for the effect of DRB-induced transcription elongation 
inhibition (Nogués et al., 2002), UV- and cisplatin-induced genotoxic stress (Muñoz et 
al., 2009) on alternative splicing. As a result of a previous study from our lab, Hnrnph3 
Exon 3 splicing was observed to be inducible upon neuronal depolarization by the KCl 
excitation of rat primary cortical neurons (An and Grabowski, 2007), and we asked if the 
alternative splicing of this inducible exon is also subject to regulation upon genotoxic 
and transcriptional stress. I hypothesized that the previously-predicted exons sharing 
the common UAGG-GGGG splicing code would be regulated similarly upon genotoxic 
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and transcriptional stress. I designed PCR primers for assaying the splicing of several 
exons throughout the study (Figure 1) (Table 1), and analyzed the splicing upon specific 
type of stress or treatment of question. 
 
 
Figure 1: Schematic representation of the PCR design for splicing analyses. PCR primers 
complementary to the flanking exons of HNRNPH1 E4, HNRNPH3 E3, and GRIN1 CI were designed, 
based on the genomic DNA sequence data obtained from the Ensembl Genome Browser. Cassette 
exons are either included or skipped. The primer locations are scaled, compared to full-length exon size. 
Human HNRNPH1 E3+E4+E5, having the size of 144+139+179 bp, is partially amplified by exonic 
primers, resulting in a 325-bp (E4 included) or 186-bp (E4 skipped) product. Human HNRNPH3 or mouse 
Hnrnph3 E2+E3+E4, having the size of 135+139+185 bp, is partially amplified by the same primers that 
amplify both transcripts to produce the products with indicated sizes. GRIN1 E18/E20 fragment, cloned by 
Dr. Kyoung Han into the pBPSV pA+ with XbaI and EcoRI, gives the indicated PCR products: 235-bp (CI 
included) or 124-bp (CI skipped). 
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Table 1: Primer sequences for the amplification of endogenous and reporter exons 
 
Primer Name 
 
Sequence 
H1E4 Forward 5’ TTGGGTGTTGAAGCATACTGG 3’ 
H1E4 Reverse 5’ CATAAGCTTTCGTGGTGGATCA 3’ 
H3E3 Forward 5’ AATGGTCCAAATGACGCTAG 3’ 
H3E3 Reverse 5’ CCAGCAATCTTCTTGGTGG 3’ 
NMDA3021 (Fwd) 5’ ATGCCCGTAGGAAGCAGATGC 3’ 
NMDA3255A (Rev) 5’ CGTCGCGGCAGCACTGTGTC 3’ 
ACTB Forward 5’ AGCTTCTTTGCAGCTCCTTC 3’ 
ACTB Reverse 5’ TCTTCTCCATGTCGTCCCAG 3’ 
 
3.1.2 The alternative splicing of Hnrnph3 Exon 3 is subject to tissue-specific and 
developmental regulation in mouse 
Tissues with different developmental needs or proliferative phenotypes have different 
splicing profiles, especially with relation to the proliferation-associated transcripts that 
contribute by giving rise to protein products that improve the adaptability of the cell to 
various types of stress. Since the hnRNP H splicing factor was shown to be differentially 
expressed in several types of cancer, and the transcript encoding hnRNP H3 was found 
to be inducible, I asked whether it has a proliferative phenotype-specific splicing in vivo. 
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Embryonic brain samples and adult cerebral cortex samples from various mice 
had higher inclusion of HNRNPH3 Exon 3, in comparison with the liver samples of adult 
mice, demonstrating the tissue specificity of the splicing of HNRNPH3 with respect to 
different proliferation rates and different developmental time points (Figure 2). The brain 
samples, belonging to a tissue with a much lower proliferation rate than the liver, has a 
distinct splicing of HNRNPH3, showing the inducibility at a tissue- and developmentally-
specific level. After this result, I decided to check for the predictions for the regulatory 
RNA motifs in or flanking the HNRNPH3 Exon 3, to understand its splicing regulation. 
 
 
Figure 2: Embryonic and mature mouse brain samples have high inclusion of Hnrnph3 exon 3, in 
contrast to lower inclusion in liver. Mouse samples (n = 3) were used for total tissue RNA extraction 
and reverse transcription, from the indicated ages of embryonic and adult mouse brain and liver tissue 
samples. PCR was performed with the endogenous HNRNPH3 primers for 26 cycles. Electrophoretic 
band intensities were measured by ImageGauge software, selecting a rectangular region encompassing 
each well of the gel, subtracting the background from the peaks in the analysis curves of the software, in 
Profile/MW setting. The graphed values above show percent inclusion and skipping, and the error bars 
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show standard deviation. ΔΨ (difference in PSI = Percent Spliced In) values show the difference in 
percent inclusion, compared to brain sample at embryonic day 18. Unpaired, two-tailed student’s t test 
was performed, and the changes in HNRNPH3 E3 inclusion were statistically significant, shown with 
asterisk. (p < 0.05) 
 
 
Figure 3: CLUSTALW alignment of human HNRNPH1 Exon 4 and HNRNPH3 Exon 3 with their 
flanking introns. Highlighted section shows the 139-bp highly-conserved exon of the HNRNPH1 and 
HNRNPH3. At the left panel; H1 stands for the HNRNPH1 transcript, H3 stands for the HNRNPH3 
transcript, H1E4 stands for HNRNPH1 Exon 4, and H3E3 stands for HNRNPH3 Exon 3. Asterisk (*) under 
the residues shows identical residues. 126 out of 139 bases are identical between HNRNPH1 Exon 4 and 
HNRNPH3 Exon 3, with 90.6% conservation. Approximately 50 bases upstream of both exons are highly 
conserved, with a disrupted stretch of 38 bases in the upstream intron. There is also conservation in the 
downstream, about a disrupted stretch of 30 bases in the downstream intron. The TAGG and GGGG 
motifs, which are part of the previously-predicted splicing code (Han et al., 2005), are underlined. 
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3.1.3 HnRNP H is an auto-regulatory splicing factor, silencing the exon of its own 
transcript in HeLa cells 
The HNRNPH3 E3 and its human paralog HNRNPH1 E4 share hnRNP A1- and hnRNP 
H-binding RNA motifs (Figure 3), triggering the question whether hnRNP H can regulate 
the splicing of its own transcript as a feedback loop mechanism. I used the HeLa CCL-2 
samples that had stable hnRNP A1 knockdown, hnRNP H knockdown and hnRNP A1 
overexpression to see their effects on the splicing of HNRNPH3 E3. I observed that the 
hnRNP H knockdown caused a strong increase in the inclusion of HNRNPH3 E3, while 
the hnRNP A1 overexpression had an anti-silencing effect (Figure 5). The hnRNP A1 
knockdown did not have a statistically significant effect, due to the presence of hnRNP 
H. Therefore, hnRNP H acts as a strong silencer of HNRNPH3 Exon 3, whereas hnRNP 
A1 acts as an anti-silencer, on the splicing of the HNRNPH3 Exon 3 in HeLa cells. 
3.1.4 HNRNPH1 E4 and HNRNPH3 E3 skipping increases upon cisplatin 
treatment, but not upon gamma-induced double strand breaks 
The splicing of proliferation-associated transcripts is affected by the treatment of cancer 
cells with several cancer drugs, raising the question whether the splicing of our 
inducible HNRNPH3 Exon 3 responds to genotoxic stress. The human paralog of the 
HNRNPH3 Exon 3, the HNRNPH1 Exon 4, has very high sequence conservation, and I 
expected them to respond similarly to cisplatin-induced single-strand genotoxic stress, 
due to the presence of the putative hnRNP H- and hnRNP A1- binding motifs (Figure 4). 
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Table 2: Human HNRNPH1 Exon 4 and HNRNPH3 Exon 3 ESEfinder motif predictions 
Table 3: Human HNRNPH1 exon 4 Human Splicing Finder enhancer motif predictions 
Seq. 
Linked SR 
Prot. Enh. Motif Value (0-100) Seq. Linked SR Prot. Enh. Motif Value (0-100) 
43 SRp55 TGTATA 79.88 548 SRp40 TCACAGG 100 
66 SC35 AGTTCCAA 75.29 549 
SF2/ASF (IgM-
BRCA1) CACAGGA 96.15 
78 SRp40 TTAAAGC 83.65 549 SF2/ASF CACAGGA 96.45 
137 SRp40 TTAATGC 82.16 562 SRp40 TGAAAAG 82.28 
141 SRp55 TGCTTA 78.98 568 SC35 GGCTCTAA 78.98 
144 SRp40 TTAAAAC 80.24 571 SRp40 TCTAAAG 80.9 
157 SC35 GAATTGTA 77.14 580 SRp40 ACACAAG 90.3 
161 SRp55 TGTATA 79.88 581 
SF2/ASF (IgM-
BRCA1) CACAAGG 79.77 
169 SRp40 TCTCAAC 85.21 581 SF2/ASF CACAAGG 81.07 
183 SRp55 TGCATA 89.8 596 SC35 GGGCACAG 76.64 
216 SRp40 TTAATGC 82.16 598 SRp40 GCACAGG 85.03 
220 SRp55 TGCATC 92.17 599 
SF2/ASF (IgM-
BRCA1) CACAGGT 94.38 
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221 SC35 GCATCCTG 79.9 599 SF2/ASF CACAGGT 94.41 
230 SC35 GTTCAGCA 77.32 627 SRp55 TATGTC 82.25 
250 SRp55 TATATA 75.97 639 SRp40 CTTATGG 78.8 
258 SC35 GTACCATG 81.99 654 SRp55 TAAATC 74.56 
294 SRp40 ATAATGG 80.96 658 SRp55 TCCATA 75.08 
304 SRp55 TTCATA 75.08 667 SRp40 TCTCTGC 87.13 
319 SRp55 TGCATA 89.8 671 SRp55 TGCTTA 78.98 
325 SRp40 TTTAAAG 79.04 674 SRp40 TTAAAAG 85.33 
341 SRp40 TGAAAGC 80.6 692 SC35 GTTTTGTA 78.06 
345 SRp55 AGCATA 77.77 702 
SF2/ASF (IgM-
BRCA1) CCTAGGT 73.23 
353 SRp40 ATTCACC 78.62 726 SC35 GATTTCCA 81.5 
358 SRp40 CCTAAAG 78.74 732 
SF2/ASF (IgM-
BRCA1) CAAACTT 70.54 
371 SRp40 ATTCTGG 84.07 734 SC35 AACTTGTG 75.35 
382 SRp40 TTTAAAG 79.04 738 SRp55 TGTGTC 86.15 
383 SRp40 TTAAAGC 83.65 742 SRp40 TCAGTCC 81.26 
389 SRp40 CTATAAG 78.32 745 SC35 GTCCCACG 84.27 
402 SC35 CATTTCTG 75.72 746 SRp40 TCCCACG 83.77 
404 SRp40 TTTCTGG 90.36 747 
SF2/ASF (IgM-
BRCA1) CCCACGT 90.77 
410 SC35 GGCTTGTG 88.32 747 SF2/ASF CCCACGT 87.94 
430 
SF2/ASF 
(IgM-BRCA1) CCCCCCT 74.92 753 SRp40 TTACACG 96.29 
431 
SF2/ASF 
(IgM-BRCA1) CCCCCTA 77.46 756 
SF2/ASF (IgM-
BRCA1) CACGCAA 70.85 
435 SRp40 CTACTGG 94.49 760 
SF2/ASF (IgM-
BRCA1) CAAACTA 72.31 
438 
SF2/ASF 
(IgM-BRCA1) CTGGGGT 74.92 760 SF2/ASF CAAACTA 74.2 
457 SC35 GGTTGAAG 75.54 774 SC35 GGTTTGAA 75.78 
495 SC35 TGCCGGTG 76.34 785 SC35 TGTCCCTA 81.13 
498 
SF2/ASF 
(IgM-
BRCA1) CGGTGGA 82.69 786 SC35 GTCCCTAG 79.16 
498 SF2/ASF CGGTGGA 78.1 787 SRp40 TCCCTAG 80.72 
503 SC35 GACTTCCA 85 801 SC35 GTCTGCTT 75.23 
506 SRp40 TTCCAGG 83.77 819 SRp55 TGAGTC 82.37 
509 
SF2/ASF 
(IgM-
BRCA1) CAGGGGA 80 830 SC35 AACCCCAA 78 
509 SF2/ASF CAGGGGA 78.1 838 SRp40 TCAATAG 85.69 
512 
SF2/ASF 
(IgM-BRCA1) GGGAGGA 73.15 851 SF2/ASF GAGACTA 76.99 
512 SF2/ASF GGGAGGA 83.17 856 SRp55 TATGGC 77.06 
520 SRp55 TACGGG 75.65 871 SRp40 TTAATGC 82.16 
522 
SF2/ASF 
(IgM-
BRCA1) CGGGGGA 82.23 884 SC35 GGCTTTAG 77.07 
522 SF2/ASF CGGGGGA 75.48 898 SRp40 TAACACC 79.52 
529 SC35 GGCCTTCG 80.82 903 
SF2/ASF (IgM-
BRCA1) CCCACCT 78.08 
544 SRp55 TGCTTC 81.35 927 SRp40 CCATAAG 80.18 
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Table 4: Human HNRNPH1 exon 4 Human Splicing Finder silencer motif predictions 
Seq. Motif Sil. motif 
Value 0-
100 Seq. Motif Sil. motif 
Value 0-
100 
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Motif 2 - 
[T/G]G[T/A]GGGG TGTTGTAA 64.46 518 Motif 2 - [T/G]G[T/A]GGGG AGTACGGG 61.28 
61 Motif 1 - CTAGAGGT CTTGAAGT 67.5 519 Motif 2 - [T/G]G[T/A]GGGG GTACGGGG 61.98 
66 Motif 3 - TCTCCCAA AGTTCCAA 65.08 520 Motif 2 - [T/G]G[T/A]GGGG TACGGGGG 70.71 
67 Motif 3 - TCTCCCAA GTTCCAAT 61.23 521 Motif 2 - [T/G]G[T/A]GGGG ACGGGGGA 63.88 
97 Motif 1 - CTAGAGGT AATGAGGT 76.44 522 Motif 2 - [T/G]G[T/A]GGGG CGGGGGAG 66.91 
99 
Motif 2 - 
[T/G]G[T/A]GGGG TGAGGTAA 69.37 523 Motif 2 - [T/G]G[T/A]GGGG 
GGGGGAG
G 67.64 
104 Motif 1 - CTAGAGGT TAAAAGGT 72.32 524 Motif 1 - CTAGAGGT GGGGAGGC 65.52 
167 Motif 3 - TCTCCCAA ATTCTCAA 66.85 524 Motif 2 - [T/G]G[T/A]GGGG GGGGAGGC 67.64 
186 Motif 1 - CTAGAGGT ATAGATAT 63.52 526 Motif 2 - [T/G]G[T/A]GGGG GGAGGCCT 67.1 
206 
Motif 2 - 
[T/G]G[T/A]GGGG TGTTGAAT 64.46 546 Motif 3 - TCTCCCAA CTTCACAG 65.99 
257 Motif 3 - TCTCCCAA TGTACCAT 66.85 548 Motif 1 - CTAGAGGT TCACAGGA 61.63 
261 Motif 1 - CTAGAGGT CCATGGGT 64.15 555 Motif 1 - CTAGAGGT AAATAGCT 66.19 
261 
Motif 2 - 
[T/G]G[T/A]GGGG CCATGGGT 62.38 563 Motif 1 - CTAGAGGT GAAAAGGC 66 
262 
Motif 2 - 
[T/G]G[T/A]GGGG CATGGGTG 61.33 569 Motif 3 - TCTCCCAA GCTCTAAA 63.5 
266 
Motif 2 - 
[T/G]G[T/A]GGGG GGTGTGTT 68.12 572 Motif 1 - CTAGAGGT CTAAAGAA 61.88 
295 
Motif 2 - 
[T/G]G[T/A]GGGG TAATGGAA 61.41 591 Motif 1 - CTAGAGGT GAATAGGG 64.09 
328 Motif 1 - CTAGAGGT AAAGAGTA 70.03 592 Motif 2 - [T/G]G[T/A]GGGG AATAGGGC 61.28 
338 
Motif 2 - 
[T/G]G[T/A]GGGG TGTTGAAA 64.46 593 Motif 1 - CTAGAGGT ATAGGGCA 60.15 
347 Motif 3 - TCTCCCAA CATACCAT 61.93 593 Motif 2 - [T/G]G[T/A]GGGG ATAGGGCA 63.35 
355 Motif 3 - TCTCCCAA TCACCTAA 72.75 598 Motif 1 - CTAGAGGT GCACAGGT 70.29 
359 Motif 1 - CTAGAGGT CTAAAGTT 69.56 602 Motif 2 - [T/G]G[T/A]GGGG AGGTGGGG 72.83 
383 Motif 1 - CTAGAGGT TTAAAGCT 64.5 603 Motif 2 - [T/G]G[T/A]GGGG 
GGTGGGG
A 97.08 
392 Motif 1 - CTAGAGGT TAAGAAGA 63.85 608 Motif 2 - [T/G]G[T/A]GGGG GGATGGAT 75.24 
405 
Motif 2 - 
[T/G]G[T/A]GGGG TTCTGGGC 62.75 612 Motif 2 - [T/G]G[T/A]GGGG GGATGGTT 74.01 
406 
Motif 2 - 
[T/G]G[T/A]GGGG TCTGGGCT 73.23 615 Motif 2 - [T/G]G[T/A]GGGG TGGTTGGT 62.75 
414 
Motif 2 - 
[T/G]G[T/A]GGGG TGTGATGT 66.35 616 Motif 2 - [T/G]G[T/A]GGGG GGTTGGTT 77.06 
416 
Motif 2 - 
[T/G]G[T/A]GGGG TGATGTTA 60.19 619 Motif 2 - [T/G]G[T/A]GGGG TGGTTGGA 62.75 
427 Motif 3 - TCTCCCAA TTGCCCCC 62.97 620 Motif 2 - [T/G]G[T/A]GGGG GGTTGGAT 78.29 
428 Motif 3 - TCTCCCAA TGCCCCCC 61.2 640 Motif 2 - [T/G]G[T/A]GGGG TTATGGTA 60.19 
429 Motif 3 - TCTCCCAA GCCCCCCT 64.53 665 Motif 3 - TCTCCCAA TCTCTCTG 74.95 
430 Motif 3 - TCTCCCAA CCCCCCTA 74.71 669 Motif 3 - TCTCCCAA TCTGCTTA 61.48 
431 Motif 3 - TCTCCCAA CCCCCTAC 63.64 677 Motif 1 - CTAGAGGT AAAGAAGA 66.66 
436 
Motif 2 - 
[T/G]G[T/A]GGGG TACTGGGG 62.75 699 Motif 3 - TCTCCCAA AGTCCTAG 61.37 
437 
Motif 2 - 
[T/G]G[T/A]GGGG ACTGGGGT 76.43 710 Motif 1 - CTAGAGGT ATTGATGT 60.67 
449 Motif 3 - TCTCCCAA TGTCCTTG 60.62 712 Motif 2 - [T/G]G[T/A]GGGG TGATGTTT 60.19 
452 
Motif 2 - 
[T/G]G[T/A]GGGG CCTTGGGT 65.43 718 Motif 3 - TCTCCCAA TTTGCCAT 68.62 
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453 
Motif 2 - 
[T/G]G[T/A]GGGG CTTGGGTT 61.33 727 Motif 3 - TCTCCCAA ATTTCCAA 66.85 
457 
Motif 2 - 
[T/G]G[T/A]GGGG GGTTGAAG 61.39 728 Motif 3 - TCTCCCAA TTTCCAAA 75.51 
460 
Motif 2 - 
[T/G]G[T/A]GGGG TGAAGGGT 81.96 744 Motif 3 - TCTCCCAA AGTCCCAC 78.98 
461 Motif 1 - CTAGAGGT GAAGGGTT 60.28 755 Motif 3 - TCTCCCAA ACACGCAA 64.08 
461 
Motif 2 - 
[T/G]G[T/A]GGGG GAAGGGTT 65.07 774 Motif 2 - [T/G]G[T/A]GGGG GGTTTGAA 61.39 
465 
Motif 2 - 
[T/G]G[T/A]GGGG GGTTGGAA 78.29 785 Motif 3 - TCTCCCAA TGTCCCTA 81.52 
475 Motif 3 - TCTCCCAA CGTGCCAA 67.93 817 Motif 2 - [T/G]G[T/A]GGGG TGTGAGTC 71.2 
481 
Motif 2 - 
[T/G]G[T/A]GGGG AAATGGGA 65.42 829 Motif 3 - TCTCCCAA TAACCCCA 65.38 
482 
Motif 2 - 
[T/G]G[T/A]GGGG AATGGGAT 65.59 830 Motif 3 - TCTCCCAA AACCCCAA 67.83 
495 
Motif 2 - 
[T/G]G[T/A]GGGG TGCCGGTG 60.41 839 Motif 1 - CTAGAGGT CAATAGAG 60.8 
499 
Motif 2 - 
[T/G]G[T/A]GGGG GGTGGACT 70.15 841 Motif 1 - CTAGAGGT ATAGAGTT 79.64 
504 Motif 3 - TCTCCCAA ACTTCCAG 75.7 845 Motif 2 - [T/G]G[T/A]GGGG AGTTGAGA 68.47 
508 Motif 1 - CTAGAGGT CCAGGGGA 72.58 848 Motif 1 - CTAGAGGT TGAGAGAC 68.18 
508 
Motif 2 - 
[T/G]G[T/A]GGGG CCAGGGGA 70.33 848 Motif 2 - [T/G]G[T/A]GGGG TGAGAGAC 69.37 
510 
Motif 2 - 
[T/G]G[T/A]GGGG 
AGGGGAG
G 63.88 900 Motif 3 - TCTCCCAA ACACCCAC 77.98 
511 Motif 1 - CTAGAGGT 
GGGGAGG
A 63.55 904 Motif 3 - TCTCCCAA CCACCTAG 63.22 
511 
Motif 2 - 
[T/G]G[T/A]GGGG 
GGGGAGG
A 67.64 908 Motif 1 - CTAGAGGT CTAGAATA 61.09 
513 
Motif 2 - 
[T/G]G[T/A]GGGG GGAGGAGT 77.13         
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Table 5: Human HNRNPH3 exon 3 Human Splicing Finder enhancer motif predictions 
Seq. 
Linked SR 
protein 
Enhancer 
motif 
Val. 0-
100 Seq. Linked SR protein 
Enhancer 
motif 
Val. 0-
100 
2 SRp40 TTACACA 82.04 271 
SF2/ASF (IgM-
BRCA1) CAGGGGA 80 
4 SRp40 ACACAGT 79.46 271 SF2/ASF CAGGGGA 78.1 
5 
SF2/ASF (IgM-
BRCA1) CACAGTG 80.92 278 SC35 GGCCTTCG 80.82 
5 SF2/ASF CACAGTG 79.85 293 SRp55 TGCTTC 81.35 
15 SRp40 TTACACT 82.04 297 SRp40 TCAAAGG 90.6 
17 SRp40 ACACTGG 92.22 298 
SF2/ASF (IgM-
BRCA1) CAAAGGA 82.62 
18 
SF2/ASF (IgM-
BRCA1) CACTGGT 81.62 298 SF2/ASF CAAAGGA 82.99 
18 SF2/ASF CACTGGT 80.14 319 
SF2/ASF (IgM-
BRCA1) CTCTGGG 76.77 
22 SC35 GGTCGCAA 81.99 321 
SF2/ASF (IgM-
BRCA1) CTGGGGA 76.69 
25 
SF2/ASF (IgM-
BRCA1) CGCAAAA 71.61 329 SRp40 ACACAAG 90.3 
39 SRp40 TTAATCC 80.3 330 
SF2/ASF (IgM-
BRCA1) CACAAGG 79.77 
73 SC35 GTATTATG 75.91 330 SF2/ASF CACAAGG 81.07 
148 
SF2/ASF (IgM-
BRCA1) CAGATGG 77.62 345 SC35 GGGCACAG 76.64 
148 SF2/ASF CAGATGG 79.62 347 SRp40 GCACAGG 85.03 
160 SRp40 TTTCAGC 86.77 348 
SF2/ASF (IgM-
BRCA1) CACAGGT 94.38 
163 
SF2/ASF (IgM-
BRCA1) CAGCCTT 78 348 SF2/ASF CACAGGT 94.41 
163 SF2/ASF CAGCCTT 78.39 371 SC35 GGATGGTG 81.32 
170 SC35 TAACACTG 76.09 403 SRp55 TGGGTC 76.48 
206 SC35 GGTTAAAG 78.12 405 SC35 GGTCACTA 90.84 
208 SRp40 TTAAAGG 88.74 407 SRp40 TCACTAT 80.84 
243 SF2/ASF TTGACGA 74.84 414 SRp55 TGCTTA 78.98 
247 
SF2/ASF (IgM-
BRCA1) CGATGGA 72.08 443 SRp40 TTTCTGG 90.36 
252 SC35 GACTACCA 86.79 446 
SF2/ASF (IgM-
BRCA1) CTGGGGT 74.92 
254 SRp40 CTACCAG 82.16 456 SRp40 TTAAAAG 85.33 
258 
SF2/ASF (IgM-
BRCA1) CAGGGGA 80 492 SC35 AACTACAG 76.46 
258 SF2/ASF CAGGGGA 78.1 494 SRp40 CTACAGA 81.74 
268 SRp40 GCACAGG 85.03 495 SRp55 TACAGA 80.71 
269 
SF2/ASF (IgM-
BRCA1) CACAGGG 92.85 514 SRp40 TTAATGC 82.16 
269 SF2/ASF CACAGGG 92.2 520 SRp40 CTAATAG 81.68 
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Table 6: Human HNRNPH3 exon 3 Human Splicing Finder silencer motif predictions 
Seq. Motif Silencer motif 
Value 
0-100 Seq. Motif 
Silencer 
motif 
Val. 0-
100 
6 Motif 1 - CTAGAGGT ACAGTGTT 60.69 297 
Motif 1 - 
CTAGAGGT TCAAAGGA 61.63 
22 Motif 3 - TCTCCCAA GGTCGCAA 66.35 300 
Motif 1 - 
CTAGAGGT AAGGAGAT 63.7 
63 Motif 3 - TCTCCCAA TCTTTCAT 63.99 320 
Motif 2 - 
[T/G]G[T/A]GGGG TCTGGGGA 83.25 
76 
Motif 2 - 
[T/G]G[T/A]GGGG TTATGGGG 72.25 340 
Motif 1 - 
CTAGAGGT GAATAGGG 64.09 
77 
Motif 2 - 
[T/G]G[T/A]GGGG TATGGGGT 83.25 341 
Motif 2 - 
[T/G]G[T/A]GGGG AATAGGGC 61.28 
79 
Motif 2 - 
[T/G]G[T/A]GGGG TGGGGTGA 70.71 342 
Motif 1 - 
CTAGAGGT ATAGGGCA 60.15 
82 
Motif 2 - 
[T/G]G[T/A]GGGG GGTGATGG 63.28 342 
Motif 2 - 
[T/G]G[T/A]GGGG ATAGGGCA 63.35 
84 
Motif 2 - 
[T/G]G[T/A]GGGG TGATGGGA 89.15 347 
Motif 1 - 
CTAGAGGT GCACAGGT 70.29 
85 
Motif 2 - 
[T/G]G[T/A]GGGG GATGGGAA 69.35 351 
Motif 2 - 
[T/G]G[T/A]GGGG AGGTGGGG 72.83 
147 Motif 1 - CTAGAGGT TCAGATGG 61.69 352 
Motif 2 - 
[T/G]G[T/A]GGGG GGTGGGGA 97.08 
149 
Motif 2 - 
[T/G]G[T/A]GGGG AGATGGGA 82.32 357 
Motif 2 - 
[T/G]G[T/A]GGGG GGATGGAG 75.24 
150 
Motif 2 - 
[T/G]G[T/A]GGGG GATGGGAA 69.35 358 
Motif 2 - 
[T/G]G[T/A]GGGG GATGGAGA 63.28 
177 Motif 3 - TCTCCCAA GTTCCCCT 67.3 361 
Motif 1 - 
CTAGAGGT GGAGAGTT 74.09 
178 Motif 3 - TCTCCCAA TTCCCCTT 61.07 361 
Motif 2 - 
[T/G]G[T/A]GGGG GGAGAGTT 65.07 
185 
Motif 2 - 
[T/G]G[T/A]GGGG TGATGGGG 89.15 365 
Motif 2 - 
[T/G]G[T/A]GGGG AGTTTGGG 68.47 
186 
Motif 2 - 
[T/G]G[T/A]GGGG GATGGGGT 80.18 366 
Motif 2 - 
[T/G]G[T/A]GGGG GTTTGGGA 72.22 
198 Motif 3 - TCTCCCAA TGTCCTTG 60.62 367 
Motif 2 - 
[T/G]G[T/A]GGGG TTTGGGAT 72.42 
201 
Motif 2 - 
[T/G]G[T/A]GGGG CCTTGGGT 65.43 371 
Motif 2 - 
[T/G]G[T/A]GGGG GGATGGTG 74.01 
202 
Motif 2 - 
[T/G]G[T/A]GGGG CTTGGGTT 61.33 372 
Motif 2 - 
[T/G]G[T/A]GGGG GATGGTGT 63.28 
208 Motif 1 - CTAGAGGT TTAAAGGG 65.03 391 
Motif 2 - 
[T/G]G[T/A]GGGG TTTTGGGG 75.3 
209 
Motif 2 - 
[T/G]G[T/A]GGGG TAAAGGGT 65.06 392 
Motif 2 - 
[T/G]G[T/A]GGGG TTTGGGGG 83.25 
210 Motif 1 - CTAGAGGT AAAGGGTT 62.91 393 
Motif 2 - 
[T/G]G[T/A]GGGG TTGGGGGT 70.71 
210 
Motif 2 - 
[T/G]G[T/A]GGGG AAAGGGTT 61.32 394 
Motif 2 - 
[T/G]G[T/A]GGGG TGGGGGTT 75.56 
214 
Motif 2 - 
[T/G]G[T/A]GGGG GGTTGGAA 78.29 398 
Motif 2 - 
[T/G]G[T/A]GGGG GGTTGTGG 72.22 
224 Motif 3 - TCTCCCAA CGTGCCAA 67.93 399 
Motif 2 - 
[T/G]G[T/A]GGGG GTTGTGGG 63.28 
230 Motif 2 - AAATGGGA 65.42 400 Motif 2 - TTGTGGGT 62.75 
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[T/G]G[T/A]GGGG [T/G]G[T/A]GGGG 
231 
Motif 2 - 
[T/G]G[T/A]GGGG AATGGGAT 65.59 401 
Motif 2 - 
[T/G]G[T/A]GGGG TGTGGGTC 88.1 
247 
Motif 2 - 
[T/G]G[T/A]GGGG CGATGGAC 68.45 419 
Motif 2 - 
[T/G]G[T/A]GGGG AAATGGGG 65.42 
253 Motif 3 - TCTCCCAA ACTACCAG 75.7 420 
Motif 2 - 
[T/G]G[T/A]GGGG AATGGGGG 76.43 
257 Motif 1 - CTAGAGGT CCAGGGGA 72.58 421 
Motif 2 - 
[T/G]G[T/A]GGGG ATGGGGGG 63.88 
257 
Motif 2 - 
[T/G]G[T/A]GGGG CCAGGGGA 70.33 422 
Motif 2 - 
[T/G]G[T/A]GGGG TGGGGGGG 87.61 
259 
Motif 2 - 
[T/G]G[T/A]GGGG AGGGGAGA 63.88 423 
Motif 2 - 
[T/G]G[T/A]GGGG GGGGGGGT 84.54 
262 Motif 1 - CTAGAGGT GGAGAAGC 64.21 424 
Motif 2 - 
[T/G]G[T/A]GGGG GGGGGGTA 72.48 
262 
Motif 2 - 
[T/G]G[T/A]GGGG GGAGAAGC 60.23 444 
Motif 2 - 
[T/G]G[T/A]GGGG TTCTGGGG 62.75 
268 Motif 1 - CTAGAGGT GCACAGGG 61.88 445 
Motif 2 - 
[T/G]G[T/A]GGGG TCTGGGGT 83.25 
270 Motif 1 - CTAGAGGT ACAGGGGA 65.75 459 
Motif 1 - 
CTAGAGGT AAAGAATT 61.6 
270 
Motif 2 - 
[T/G]G[T/A]GGGG ACAGGGGA 73.38 494 
Motif 1 - 
CTAGAGGT CTACAGAT 70.35 
272 
Motif 2 - 
[T/G]G[T/A]GGGG AGGGGAGG 63.88 500 
Motif 2 - 
[T/G]G[T/A]GGGG ATTTGGGT 68.47 
273 Motif 1 - CTAGAGGT GGGGAGGC 65.52 501 
Motif 2 - 
[T/G]G[T/A]GGGG TTTGGGTG 71.2 
273 
Motif 2 - 
[T/G]G[T/A]GGGG GGGGAGGC 67.64 503 
Motif 2 - 
[T/G]G[T/A]GGGG TGGGTGGG 70.71 
275 
Motif 2 - 
[T/G]G[T/A]GGGG GGAGGCCT 67.1 504 
Motif 2 - 
[T/G]G[T/A]GGGG GGGTGGGG 76.58 
294 Motif 3 - TCTCCCAA GCTTCAAA 63.5 505 
Motif 2 - 
[T/G]G[T/A]GGGG GGTGGGGA 97.08 
 
 
The scores for the predicted RNA motifs in Tables 2-6 were used to construct the 
map of regulatory RNA motifs in Figure H. I observed overlaps between an extended 
region of hnRNP H binding and ASF/SF2 binding within both the HNRNPH1 Exon 4 and 
the HNRNPH3 Exon 3 (Figure 4). I predicted that hnRNP H would have an effect on the 
splicing of HNRNPH3 Exon 3, to regulate the splicing of its own transcript. 
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Figure 4: The map of regulatory RNA motifs for HNRNPH1 Exon 4 and HNRNPH3 Exon 3, based on 
the Human Splicing Finder and ESEfinder prediction scores. H1E4 stands for HNRNPH1 Exon 4; 
H3E3 stands for HNRNPH3 exon 3. H1I4 stands for HNRNPH1 Intron 4; H3I3 stands for HNRNPH3 
Intron 3. Black thin boxed AGGG and GGGA sequences are predicted hnRNP H binding motifs. 
Underlined sequences are predicted ASF/SF2 binding motifs. Asterisk (*) shows exact sequence 
conservation. In the exonic section upstream of the 5’ splice site, the TAGG is the putative hnRNP A1 
motif. Downstream of the 5’ splice site, the GGGG is the hnRNP H binding motif. The scores higher than 
80 percent were considered, based on the values in Tables 2-6.  
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Figure 5: HnRNP H is a strong silencer, and hnRNP A1 acts as an anti-silencer, on the 
endogenous HNRNPH3 exon 3 in HeLa cells. HnRNP A1 and hnRNP H were knocked down (n = 3) in 
6-well plates with 20 ng siRNA per well, compared to the non-targeting control siRNA. HnRNP A1 is 
overexpressed in HeLa cells as part of pcDNA3 vector. Total RNA was isolated and reverse transcribed. 
PCR was performed with the endogenous HNRNPH3 E2/E4 primers (26 cycles), and the products were 
run on 1.8% agarose gel. The values show percent inclusion and skipping, and the error bars show the 
standard deviation. ΔΨ (difference in PSI = Percent Spliced In) values show the difference in percentage 
of inclusion, compared to the HeLa control samples. Unpaired, two-tailed student’s t test was performed, 
and the changes in the HNRNPH3 E3 inclusion were found to be statistically significant, shown with 
asterisk. (p < 0.05) 
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 The inclusion of HNRNPH1 Exon 4 and HNRNPH3 Exon 3 decreased, and their 
skipping increased in a dose-dependent manner upon cisplatin treatment in HeLa cells 
(Figure 6). However, the gamma irradiation-induced double strand breaks, confirmed by 
the increase in the gamma-H2AX, did not cause a statistically significant change in the 
splicing of the HNRNPH3 Exon 3 in U2OS cells (Figure 7), possibly due to the different 
types of DNA damage and the diverse repair mechanisms acting differently in both 
cases. It is also possible that there can be cell type-specific and context-dependent 
effects, because the double-strand breaks can occur at random loci upon IR treatment. 
 
 
Figure 6: Cisplatin-induced DNA damage causes a dose-dependent increase in the skipping of the 
endogenous HNRNPH1 exon 4 and HNRNPH3 exon 3 in HeLa cells. HeLa cells (n = 3) were treated 
separately with 0-20-40 μM cisplatin for 14 hours. Total RNA was isolated and reverse transcribed. PCR 
was performed with endogenous A) HNRNPH1 E3/E5 and B) HNRNPH3 E2/E4 primers (26 cycles). The 
PCR products were run on 1.8% agarose gel. The electrophoretic bands were analyzed by the 
ImageGauge software. The values show percent inclusion and skipping, and the error bars show the 
standard deviation. ΔΨ (difference in PSI = Percent Spliced In) values show the difference in percentage 
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of inclusion, compared to the HeLa samples treated with 0 μM cisplatin. Unpaired two-tailed student’s t 
test was performed, and the changes in the endogenous HNRNPH1 E4 and HNRNPH3 E3 inclusion were 
found to be statistically significant. (p < 0.05) 
 
 
Figure 7: Gamma irradiation-induced double strand DNA breaks do not affect the splicing of the 
endogenous HNRNPH3 exon 3 in U2OS human osteosarcoma cells. The U2OS cells (n = 3) were 
grown on 60 mm plates overnight, and they were treated with 2.8-3 Gy of γ-radiation by exposing them to 
137Cs for 15 minutes. Following the γ-IR treatment, the U2OS cells were either harvested immediately (0h 
Post-IR), or allowed to recover until the indicated time points. A) Double strand DNA breaks induced by γ-
IR do not cause a change in the splicing of HNRNPH3 Exon 3. PCR was performed with the endogenous 
HNRNPH3 E2/E4 primers (26 cycles), and the products were run on 1.8% agarose gel. The values show 
percent inclusion and skipping, and the error bars show the standard deviation. ΔΨ values show the 
difference in percentage of inclusion, compared to untreated U2OS cells. B) Double strand DNA breaks 
are confirmed by Western Blot against the phosphoserine 139 γ-H2AX ab. β-tubulin is the loading control. 
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3.1.5 DRB-induced transcription stress causes an alternative splicing response 
that is similar to cisplatin-induced genotoxic stress 
The cisplatin-induced single-strand DNA damage can be repaired by the transcription-
coupled repair (Damsma et al., 2007), and can cause changes in splicing by changing 
the rate of transcription (Thomas and Lieberman, 2013). Therefore, I asked whether the 
transcriptional stress affects the splicing of HNRNPH1 and HNRNPH3 in HeLa cells. 
 The 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) molecule is a known 
inhibitor of transcription elongation, and its effects on the splicing of several exons were 
previously studied. However, the regulatory RNA motifs that affect the splicing response 
to genotoxic and/or transcriptional stress remain unknown, and its effect on the splicing 
of HNRNPH1 and HNRNPH3 was not shown. 
 Poly(G) motifs and their location-dependent effects were previously studied, and 
the G-rich motifs adjacent to the 5’ splice sites in vertebrate introns were observed to 
have enhancer effects, contributing to the selection of the splice site and the intron-exon 
boundaries, and affecting the strength or weakness of the splice site (McCullough and 
Berget, 1997; Carlo et al., 2000; McCullough and Berget, 2000; Xiao et al., 2009). In a 
genomewide search, an enrichment of GU-rich sequences was observed in a subset of 
exons with higher inclusion upon DRB treatment (Fong et al., 2014). Since the 5’ splice 
site GGGG motif was conserved across the human HNRNPH1 Exon 4 and HNRNPH3 
Exon 3, I asked whether DRB would act to increase the inclusion of human endogenous 
HNRNPH1 Exon 4 and HNRNPH3 Exon 3. 
The previously-published functions of the 5’ splice site poly(G) sequences do not 
seem to fit the effect of DRB treatment that I observed on the splicing of HNRNPH1 and 
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HNRNPH3. I tested the effect of DRB-induced transcription elongation inhibition in HeLa 
cells, and I observed that there is a dose-dependent increase in the skipping of human 
endogenous HNRNPH1 Exon 4 and HNRNPH3 Exon 3 upon DRB treatment (Figure 8). 
 During the gel quantification, the background can be uneven or misleading. The 
fluoroconjugated primers allow the quantification of the specific PCR product without the 
agarose gel background EtBr. For this reason, I used TAMRA-conjugated HNRNPH3 
Exon 3 primer to confirm the change in the inclusion and skipping. The Exon 3 skipping 
increased with a similar trend and bigger magnitude upon same doses of DRB-induced 
transcription elongation inhibition in HeLa cells (Figure 9). 
 
 
Figure 8: DRB-induced transcription elongation inhibition causes dose-dependent decrease in the 
inclusion of endogenous HNRNPH1 exon 4 and HNRNPH3 exon 3. A) HNRNPH1 Exon 4 (E4). B) 
HNRNPH3 Exon 3 (E3). HeLa cells (n = 3) were treated separately with the indicated doses of DRB for 
24 hours. Total RNA was isolated and reverse transcribed. PCR was performed with HNRNPH1 E3/E5 
and HNRNPH3 E2/E4 primers respectively (26 cycles), and the PCR products were run on 1.8% agarose 
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gel. Electrophoretic bands were analyzed by ImageGauge software. Numbers represent percentage of 
exon inclusion and skipping. ΔΨ (difference in PSI = Percent Spliced In) values show the difference in 
percentage of inclusion; compared to 0 µM DRB. Unpaired two-tailed student’s t test was performed, and 
the changes in the endogenous HNRNPH1 E4 and HNRNPH3 E3 inclusion were found to be statistically 
significant. (p < 0.05) 
 
Figure 9: DRB-induced increase in the skipping of the endogenous HNRNPH3 exon 3 is confirmed 
by PCR with fluoroconjugated primers. HeLa cells (n = 3) were treated separately with the indicated 
doses of DRB for 24 hours. Total RNA was isolated and reverse transcribed. PCR was performed with the 
TAMRA-conjugated HNRNPH3 E2 forward and untagged E4 (*-E2/E4) primers for 26 cycles, and the 
PCR products were run on 1.8% agarose gel without Ethidium Bromide. The bands were visualized at 
540/575 nm (excitation/emission), and the analysis was performed with the ImageGauge software. 
Numbers represent percentage of exon inclusion and skipping. ΔΨ (difference in PSI = Percent Spliced 
In) values show the difference in percentage of inclusion; compared to 0 µM DRB. Asterisks above the 
column charts show statistically significant difference. Unpaired, two-tailed student’s t test was performed, 
and the exon inclusion changes were found to be statistically significant (p < 0.05). 
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3.2 THE HNRNP H-REGULATED GRIN1 CI CASSETTE EXON RESPONDS TO 
DRB AND TRANSCRIPTIONAL PAUSE-RELEASE 
The GRIN1 CI exon, which is subject to tissue-specific and developmentally-specific 
regulation (Black and Grabowski, 2003) similar to HNRNPH3 Exon 3, is also under the 
regulation of hnRNP A1 and hnRNP H similar to that of HNRNPH3 Exon 3 (Han et al., 
2005). These exons were found together in the genomewide search for a UAGG-GGGG 
splicing code (Han et al., 2005), and is inducible upon depolarization by KCl treatment 
(An and Grabowski, 2007), which raised the possibility of using the previously-cloned 
GRIN1 splicing reporter constructs and their GGGG mutants as a model system to test 
the effect of poly(G) stretches and the UAGG-GGGG splicing code in the mechanism of 
alternative splicing upon DRB-induced transcription stress. 
The wild-type splicing reporter and the mutants of the wild-type CI construct are 
as described (Han et al., 2005) (Figure 10). C1wt0 is the wild-type rat GRIN1 CI exon, 
cloned into the pBPSV pA+ reporter, as described (Han et al., 2005). The E17 mutant 
has two mutations in each UAGG motif, turning them into UAAU (Han et al., 2005) 
(Figures 10-11). The T8 mutant is a triple mutant, destroying two exonic UAGG sites 
and the +6 GGGG close to the 5’ splice site (Han et al., 2005) (Figures 10-11). 5m2 and 
5m4 are GGGG mutants, at the +6 after the 5’ splice site downstream of the CI cassette 
exon (Han et al., 2005) (Figures 10-11). The aim of using these UAGG and GGGG 
mutants is to find out whether the mutated motifs affect the DRB-induced splicing 
changes, if they cause increased skipping or inclusion, or whether they have any role. 
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Figure 10: The schematic of the mutants, with respect to the overlapping binding sites for U1 
snRNP and hnRNP H at the 5’ splice site, and the exonic binding sites for hnRNP A1. The 
overlapping U1 snRNP and hnRNP H binding sites at the 5’ splice site immediately downstream of the CI 
exon, and the splicing reporter mutant constructs used for the DRB-induced transcriptional pausing and 
pause-release experiment, along with the location of these binding sites with respect to the CI exon are 
shown. CIwt0 stands for the wild type pA+ CI construct. 5m2 and 5m4 are three-nucleotide mutations at 
the +6 GGGG motif immediately downstream of the 5’ splice site. E17 is a double mutant with 2 UAGG 
sites mutated into UAAU. Combining the mutated motif in E17 and the mutated motif in 5m2, T8 is a triple 
mutant with two UAGGs and one GGGG destroyed. Asterisk with a colon shows 5’ splice site. Lowercase 
shows the intron, uppercase shows the exon. Constructs were cloned by Kyounga Han (Han et al., 2005). 
 
Table 7: GRIN1 CI exon Human Splicing Finder enhancer motif predictions 
Seq 
Linked SR 
protein Enh. motif 
Value 0-100 
(variation) Seq 
Linked SR 
protein Enh. motif 
Value 0-100 
(variation) 
7 SRp40 agtctgg 81.02 (+13.40 %) 234 SC35 GCCTCCAG 79.84 (+19.20 %) 
12 SC35 ggctgttg 82.54 (+30.04 %) 242 SRp40 CTTCAAG 86.29 (+37.44 %) 
19 SC35 ggtccgtc 77.01 (+7.87 %) 248 
SF2/ASF (IgM-
BRCA1) GAGACGT 70.77 (+0.88 %) 
21 SRp55 tccgtc 81.35 (+28.65 %) 248 SF2/ASF GAGACGT 87.30 (+53.01 %) 
24 SC35 gtctgttg 78.55 (+14.03 %) 252 
SF2/ASF (IgM-
BRCA1) CGTAGGT 80.69 (+34.52 %) 
34 
SF2/ASF 
(IgM-
BRCA1) cacagtg 80.92 (+35.31 %) 252 SF2/ASF CGTAGGT 78.33 (+19.82 %) 
34 SF2/ASF cacagtg 79.85 (+25.42 %) 257 SC35 GTCCTCCA 84.63 (+38.41 %) 
39 SRp55 tgaggc 77.19 (+12.74 %) 266 SRp40 AGACACG 86.95 (+40.45 %) 
46 
SF2/ASF 
(IgM-
BRCA1) ggcagga 76.08 (+18.87 %) 267 
SF2/ASF (IgM-
BRCA1) GACACGg 72.15 (+5.57 %) 
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46 SF2/ASF ggcagga 84.62 (+43.10 %) 267 SF2/ASF GACACGg 86.55 (+50.21 %) 
52 SRp40 agtcagg 82.51 (+20.23 %) 269 
SF2/ASF (IgM-
BRCA1) CACGgta 71.00 (+1.66 %) 
53 SF2/ASF gtcaggg 76.47 (+12.92 %) 286 SC35 caccccag 79.04 (+16.00 %) 
58 SC35 ggcctgag 83.47 (+33.73 %) 286 
SF2/ASF (IgM-
BRCA1) cacccca 81.92 (+38.70 %) 
61 
SF2/ASF 
(IgM-
BRCA1) ctgagtg 74.69 (+14.18 %) 286 SF2/ASF cacccca 79.27 (+23.26 %) 
66 SRp40 tgaccgg 84.67 (+30.07 %) 288 
SF2/ASF (IgM-
BRCA1) ccccagt 72.92 (+8.18 %) 
70 
SF2/ASF 
(IgM-
BRCA1) cggccag 76.92 (+21.74 %) 290 SRp40 ccagtcc 79.10 (+4.66 %) 
83 
SF2/ASF 
(IgM-
BRCA1) cagcggc 79.15 (+29.31 %) 293 SC35 gtcccgcg 86.48 (+45.80 %) 
83 SF2/ASF cagcggc 76.41 (+12.70 %) 295 
SF2/ASF (IgM-
BRCA1) cccgcgt 77.54 (+23.83 %) 
84 SRp55 agcggc 78.85 (+19.10 %) 297 SRp55 cgcgtc 90.76 (+64.66 %) 
87 SC35 ggccccaa 90.96 (+63.79 %) 299 SC35 cgtctctg 79.35 (+17.23 %) 
89 SRp40 ccccaag 80.06 (+9.03 %) 305 SRp40 tgactcc 86.65 (+39.08 %) 
90 
SF2/ASF 
(IgM-
BRCA1) cccaagg 74.54 (+13.66 %) 306 SC35 gactcctc 82.48 (+29.79 %) 
91 
SF2/ASF 
(IgM-
BRCA1) ccaagga 77.38 (+23.31 %) 311 
SF2/ASF (IgM-
BRCA1) ctccctt 77.62 (+24.09 %) 
107 
SF2/ASF 
(IgM-
BRCA1) ggcaggt 74.31 (+12.87 %) 311 SF2/ASF ctccctt 73.33 (+1.28 %) 
107 SF2/ASF ggcaggt 82.59 (+35.55 %) 318 SC35 gccccgtg 81.93 (+27.58 %) 
113 SRp55 tgtggc 80.97 (+27.19 %) 319 
SF2/ASF (IgM-
BRCA1) ccccgtg 72.54 (+6.88 %) 
116 SC35 ggccgcca 87.83 (+51.22 %) 322 SRp55 cgtgtc 80.84 (+26.70 %) 
122 
SF2/ASF 
(IgM-
BRCA1) cacgctt 70.85 (+1.14 %) 328 SRp40 tgtctcc 80.36 (+10.40 %) 
135 SRp40 ctaatcg 83.23 (+23.51 %) 329 SC35 gtctccct 76.77 (+6.88 %) 
146 SRp55 tacata 85.90 (+46.04 %) 334 SRp40 cctctcc 83.11 (+22.96 %) 
184 
SF2/ASF 
(IgM-
BRCA1) AGCCCGA 72.77 (+7.66 %) 337 
SF2/ASF (IgM-
BRCA1) ctccctt 77.62 (+24.09 %) 
184 SF2/ASF AGCCCGA 76.99 (+14.86 %) 337 SF2/ASF ctccctt 73.33 (+1.28 %) 
188 SC35 CGACCCTA 78.55 (+14.03 %) 348 SRp40 tcccacc 78.68 (+2.75 %) 
189 SC35 GACCCTAA 78.18 (+12.55 %) 349 
SF2/ASF (IgM-
BRCA1) cccacct 78.08 (+25.66 %) 
215 SC35 GGCTATCA 78.43 (+13.53 %) 351 SC35 cacctctg 80.64 (+22.40 %) 
227 
SF2/ASF 
(IgM-
BRCA1) CACCCTG 79.38 (+30.09 %) 353 SRp40 cctctgc 84.97 (+31.43 %) 
227 SF2/ASF CACCCTG 77.64 (+17.23 %) 365 SRp40 cttcaac 81.20 (+14.22 %) 
233 SC35 GGCCTCCA 88.63 (+54.43 %) 
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Table 8: GRIN1 CI exon Human Splicing Finder silencer motif predictions 
Seq.  Motif Sil. motif 
Value 0-100 
(var.) Seq.  Motif Sil. motif 
Value 0-100 
(var.) 
7 
Motif 2 - 
[T/G]G[T/A]GGGG agtctggc 61.28 (+3.20 %) 211 
Motif 2 - 
[T/G]G[T/A]GGGG TTAGGGCT 70.18 (+25.45 %) 
15 
Motif 2 - 
[T/G]G[T/A]GGGG tgttggtc 
80.14 (+50.35 
%) 216 Motif 3 - TCTCCCAA GCTATCAC 60.21 (+0.52 %) 
27 
Motif 2 - 
[T/G]G[T/A]GGGG tgttgagc 
75.30 (+38.24 
%) 222 Motif 3 - TCTCCCAA ACCTCCAC 60.79 (+1.99 %) 
37 
Motif 1 - 
CTAGAGGT agtgaggc 
68.14 (+20.36 
%) 223 Motif 3 - TCTCCCAA CCTCCACC 67.86 (+19.65 %) 
37 
Motif 2 - 
[T/G]G[T/A]GGGG agtgaggc 
76.43 (+41.06 
%) 226 Motif 3 - TCTCCCAA CCACCCTG 70.99 (+27.49 %) 
39 
Motif 2 - 
[T/G]G[T/A]GGGG tgaggcag 
69.37 (+23.43 
%) 234 Motif 3 - TCTCCCAA GCCTCCAG 61.64 (+4.10 %) 
47 
Motif 2 - 
[T/G]G[T/A]GGGG gcaggagt 60.23 (+0.56 %) 235 Motif 3 - TCTCCCAA CCTCCAGC 65.36 (+13.40 %) 
48 
Motif 1 - 
CTAGAGGT caggagtc 63.23 (+8.08 %) 245 
Motif 1 - 
CTAGAGGT CAAGAGAC 79.62 (+49.05 %) 
52 
Motif 2 - 
[T/G]G[T/A]GGGG agtcaggg 61.28 (+3.20 %) 247 
Motif 1 - 
CTAGAGGT AGAGACGT 73.34 (+33.36 %) 
54 
Motif 2 - 
[T/G]G[T/A]GGGG tcagggcc 
70.18 (+25.45 
%) 252 
Motif 2 - 
[T/G]G[T/A]GGGG CGTAGGTC 63.08 (+7.71 %) 
62 
Motif 2 - 
[T/G]G[T/A]GGGG tgagtgac 
69.37 (+23.43 
%) 258 Motif 3 - TCTCCCAA TCCTCCAA 72.75 (+31.86 %) 
66 
Motif 2 - 
[T/G]G[T/A]GGGG tgaccggc 
65.06 (+12.65 
%) 259 Motif 3 - TCTCCCAA CCTCCAAA 82.26 (+55.65 %) 
69 
Motif 3 - 
TCTCCCAA ccggccag 63.22 (+8.05 %) 262 
Motif 1 - 
CTAGAGGT CCAAAGAC 60.50 (+1.26 %) 
78 
Motif 3 - 
TCTCCCAA cctggcag 61.36 (+3.40 %) 272 
Motif 2 - 
[T/G]G[T/A]GGGG Ggtaaggg 65.03 (+12.58 %) 
82 
Motif 1 - 
CTAGAGGT gcagcggc 
65.09 (+12.73 
%) 273 
Motif 2 - 
[T/G]G[T/A]GGGG gtaagggg 61.98 (+4.96 %) 
82 
Motif 2 - 
[T/G]G[T/A]GGGG gcagcggc 60.23 (+0.56 %) 274 
Motif 1 - 
CTAGAGGT taagggga 65.15 (+12.88 %) 
87 
Motif 3 - 
TCTCCCAA ggccccaa 
68.21 (+20.53 
%) 274 
Motif 2 - 
[T/G]G[T/A]GGGG taagggga 80.20 (+50.51 %) 
88 
Motif 3 - 
TCTCCCAA gccccaag 61.64 (+4.10 %) 279 
Motif 2 - 
[T/G]G[T/A]GGGG ggaagagc 61.98 (+4.96 %) 
95 
Motif 2 - 
[T/G]G[T/A]GGGG ggagcagg 60.23 (+0.56 %) 280 
Motif 1 - 
CTAGAGGT gaagagca 71.99 (+29.97 %) 
102 
Motif 2 - 
[T/G]G[T/A]GGGG gcaagggc 61.98 (+4.96 %) 285 Motif 3 - TCTCCCAA gcacccca 71.43 (+28.57 %) 
103 
Motif 1 - 
CTAGAGGT caagggca 
65.85 (+14.62 
%) 286 Motif 3 - TCTCCCAA caccccag 66.96 (+17.41 %) 
103 
Motif 2 - 
[T/G]G[T/A]GGGG caagggca 60.31 (+0.77 %) 292 Motif 3 - TCTCCCAA agtcccgc 65.37 (+13.41 %) 
108 
Motif 2 - 
[T/G]G[T/A]GGGG gcaggtgt 60.23 (+0.56 %) 301 Motif 3 - TCTCCCAA tctctgac 67.60 (+18.99 %) 
111 
Motif 2 - 
[T/G]G[T/A]GGGG ggtgtggc 
80.18 (+50.45 
%) 307 Motif 3 - TCTCCCAA actcctcc 65.01 (+12.53 %) 
113 
Motif 2 - 
[T/G]G[T/A]GGGG tgtggccg 
73.23 (+33.07 
%) 310 Motif 3 - TCTCCCAA cctccctt 83.14 (+57.85 %) 
117 
Motif 3 - 
TCTCCCAA gccgccac 62.06 (+5.16 %) 316 Motif 3 - TCTCCCAA ttgccccg 62.55 (+6.37 %) 
167 Motif 1 - AAAGAG 70.09 (+25.22 330 Motif 3 - TCTCCCAA tctccctc 92.56 (+81.39 %) 
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CTAGAGGT TG %) 
169 
Motif 1 - 
CTAGAGGT 
AGAGTG
GT 
74.65 (+36.62 
%) 332 Motif 3 - TCTCCCAA tccctctc 60.05 (+0.11 %) 
169 
Motif 2 - 
[T/G]G[T/A]GGGG 
AGAGTG
GT 
73.38 (+33.44 
%) 334 Motif 3 - TCTCCCAA cctctccc 67.86 (+19.65 %) 
171 
Motif 2 - 
[T/G]G[T/A]GGGG 
AGTGGT
AG 
65.59 (+13.98 
%) 336 Motif 3 - TCTCCCAA tctccctt 88.95 (+72.38 %) 
174 
Motif 2 - 
[T/G]G[T/A]GGGG 
GGTAGA
GC 
65.03 (+12.58 
%) 341 Motif 3 - TCTCCCAA cttaccat 62.81 (+7.02 %) 
175 
Motif 1 - 
CTAGAGGT 
GTAGAG
CA 
73.12 (+32.80 
%) 346 Motif 3 - TCTCCCAA catcccac 82.71 (+56.79 %) 
180 
Motif 1 - 
CTAGAGGT 
GCAGAG
CC 
71.74 (+29.35 
%) 355 Motif 3 - TCTCCCAA tctgcccc 73.67 (+34.18 %) 
188 
Motif 3 - 
TCTCCCAA 
CGACCC
TA 60.38 (+0.95 %) 356 Motif 3 - TCTCCCAA ctgcccca 60.45 (+1.12 %) 
210 
Motif 2 - 
[T/G]G[T/A]GGGG 
TTTAGG
GC 
68.11 (+20.27 
%) 357 Motif 3 - TCTCCCAA tgccccat 68.71 (+21.77 %) 
211 
Motif 1 - 
CTAGAGGT 
TTAGGG
CT 
65.80 (+14.51 
%) 364 Motif 3 - TCTCCCAA tcttcaac 67.60 (+18.99 %) 
 
 
Figure 11: The map of regulatory RNA motifs for GRIN1 CI exon and its flanking introns, based on 
the Human Splicing Finder prediction scores. The scores higher than 80 percent were considered, 
based on the values in Tables 7-8. TAGA and TAGG motifs are predicted for the binding of hnRNP A1. 
AGGG / GGGA / GGGG motifs are predicted for the binding of hnRNP H. There are overlaps between 
SRSF1, SRSF2 and SRSF5. The sites of the mutations (Han et al., 2005) were shown with the thick box 
and arrows. The map was adapted from Kyounga Han, with the recent version of the HSF online splicing 
motif prediction tool. 
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3.2.1 The alternative splicing of HNRNPH1 E4 and hnRNP H-regulated GRIN1 CI 
exon is regulated similarly upon transcription stress 
The structural similarities between HNRNPH1 Exon 4 and GRIN1 CI exon, and their 
similar splicing regulation by hnRNP A1 and hnRNP H caused me to ask whether their 
splicing regulation is similar upon transcriptional stress, and whether GRIN1 can be 
used as a model to investigate the role of UAGG and GGGG motifs in the alternative 
splicing regulation upon transcriptional stress. Since the brain-specific GRIN1 is not 
expressed in HeLa cells, I transfected the CI cassette exon as part of a pA+ splicing 
reporter construct into HeLa cells. 
Upon DRB treatment, we observed a dose-dependent increase in the skipping of 
GRIN1 CI exon, similar to the HNRNPH1 Exon 4 splicing in HeLa cells (Figure 8). In 
light of the data showing that DRB-induced transcription elongation inhibition caused 
increased skipping of GRIN1 CI exon (Figure 12), I constructed an RNA map of GRIN1 
CI (Figure 11) as an adaptation of the previously published work (Han et al., 2005) in 
order to elucidate the splicing motifs that are responsible for the effect of DRB, based 
on the RNA motif predictions of Human Splicing Finder and ESEfinder algorithms. 
There were 2 exonic UAGG motifs and 2 exonic UAGA motifs identified as possible 
hnRNP A1-binding sites, as well as 1 exonic AGGG and 1 intronic GGGG motifs as 
possible hnRNP H-binding sites (Figure 11). The UAGG motifs were previously found 
by our lab to be bound by purified hnRNP H, albeit with a lower affinity than AGGG or 
GGGA motifs (Grabowski Lab, unpublished data). 
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Figure 12: Endogenous HNRNPH1 exon 4 and pA+ reporter-cloned GRIN1 CI exon respond 
similarly to DRB-induced transcription elongation inhibition in the GRIN1 pA+ reporter-transfected 
HeLa cells. A) GRIN1 CI. B) HNRNPH1 E4. HeLa cells (n = 3) were grown and transfected separately 
with pA+-C1wt0 expressing wild-type GRIN1 CI cassette exon and its flanking introns. After removing the 
transfection medium, the indicated doses of DRB were added onto the cells and they were incubated with 
DRB for 14 hours. Total RNA was isolated and reverse transcribed. PCR was performed with CI and 
HNRNPH1 E3/E5 primers (26 cycles), and the products were run on 1.8% agarose gel. The 
electrophoretic bands were analyzed by ImageGauge software. Numbers represent percent inclusion and 
skipping. ΔΨ (difference in PSI = Percent Spliced In) values show the difference in percentage of 
inclusion; compared to 0 µM DRB. Asterisks above the column charts show statistically significant 
difference. Unpaired, two-tailed student’s t test was performed, and the changes in the GRIN1 CI and 
HNRNPH1 E4 inclusion were found to be statistically significant. (p < 0.05) 
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Figure 13: DRB causes an increase in the pA+ reporter-cloned GRIN1 CI skipping in wild type-, but 
the response is truncated in the UAGG mutant-transfected HeLa cells. 250 ng/well E17 (UAGG 
double mutant) and T8 (UAGGs + GGGG triple mutant) were transfected to HeLa cells (n = 3), versus 
wild-type C1wt0 to each well and the transfection medium was replaced 4 hours post-transfection by 
DMEM + 10% FBS with 0 µM versus 30 µM DRB. Total RNA was isolated and reverse transcribed. PCR 
was performed with CI primers (26 cycles), and the products were run on 1.8% agarose gel. The 
electrophoretic bands were analyzed by ImageGauge software. Numbers represent percent exon 
inclusion and skipping. Asterisks above the column chart show statistically significant difference. 
Unpaired, two-tailed student’s t test was performed, and the changes in the GRIN1 CI inclusion were 
found to be statistically significant. (p < 0.05) 
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3.2.2 UAGG and GGGG motifs are necessary for the response to DRB in the pA+ 
reporter-transfected HeLa cells 
After observing the effect of DRB on the splicing of GRIN1 CI cassette exon, and by 
making a map of putative regulatory RNA motifs, I asked which of the RNA motifs were 
responsible for the splicing effect of DRB. I chose single and combined mutations of the 
UAGGs and GGGG to monitor the effects of DRB on splicing, since the shared RNA 
motifs include two exonic UAGG motifs and a GGGG close to 5´ splice site. I used E17, 
T8, 5m2, and 5m4 mutants, as described (Han et al., 2005). 
I transfected the wild type versus mutant pA+ splicing reporters into HeLa cells, 
and afterwards I treated them with DRB for 14 hours. E17, the mutant with 2 UAGG 
motifs destroyed, had a truncated response to DRB, whereas the triple mutant T8 
lacking 2 UAGGs and 1 GGGG was almost completely unresponsive to DRB treatment 
(Figure 13). Regardless of whether the wild type or the mutant splicing reporter were 
transfected, the splicing of endogenous HNRNPH1 Exon 4 responded similarly to DRB 
treatment, as an internal control (Figure 15). 
These data showed that the two UAGG motifs as well as the GGGG motif are 
required for the splicing response to DRB-induced transcriptional stress. The mutated 
UAGG motifs cause an increase in CI inclusion in untreated control cells (Figure 13). 
GGGG motif causes a statistically-significant increase in exon inclusion in control cells 
without DRB treatment, showing that UAGG and GGGG motifs are acting as silencers 
for the CI exon (Figure 14). 
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Figure 14: The intronic GGGG silencer motif immediately downstream of the 5’ splice site inhibits 
the effect of DRB on GRIN1 cassette exon splicing. 250 ng of the wild-type C1wt0 and the GGGG 
mutants 5m2 and 5m4 were transfected into each well, and after 4 hours the transfection medium was 
replaced by the DMEM + 10% FBS including 0 µM or 30 µM DRB. Total RNA was isolated, reverse 
transcribed, and the PCR was performed with the primers recognizing the flanking exons of the GRIN1 CI 
cassette exon (26 cycles). PCR products were run on 1.8% agarose gel for 2 hours. The electrophoretic 
bands were analyzed by ImageGauge software. Numbers represent percentage of inclusion and skipping. 
ΔΨ (difference in PSI = Percent Spliced In) values show the difference in percentage of inclusion; 
compared to 0 µM DRB of each reporter transfection. Asterisks above the column chart show statistically 
significant difference. Unpaired, two-tailed student’s t test was performed, and the changes in the GRIN1 
CI inclusion were found to be statistically significant. (p < 0.05) 
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Figure 15: DRB treatment causes an increase in the endogenous HNRNPH1 exon 4 skipping in 
wild type and mutant GRIN1 pA+ reporter-transfected HeLa cells. 250 ng of the wild-type C1wt0 and 
the GGGG mutants 5m2 and 5m4 were transfected into each well, and after 4 hours the transfection 
medium was replaced by the DMEM + 10% FBS including 0 µM or 30 µM DRB. Total RNA was isolated, 
reverse transcribed, and the PCR was performed with HNRNPH1 E3/E5 primers (26 cycles). PCR 
products were run on 1.8% agarose gel for 2 hours. The electrophoretic bands were analyzed by 
ImageGauge software. Numbers represent percentage of inclusion and skipping. ΔΨ (difference in PSI = 
Percent Spliced In) values show the difference in percentage of inclusion; compared to 0 µM DRB of each 
reporter transfection. Asterisks above the column chart show statistically significant difference. Unpaired, 
two-tailed student’s t test was performed, and the changes in the E4 inclusion were found to be 
statistically significant. (p < 0.05) 
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3.2.3 Mutated GGGG motif leads to a bigger splicing response to DRB in the pA+ 
reporter-transfected HeLa cells 
In the earlier studies, the 5’ splice site sequences were found to be enhancers that 
determine intron-exon boundaries, strength of splice sites, and recruiting U1 snRNP to 
the 5’ splice site (McCullough and Berget, 1997; Carlo et al., 2000; McCullough and 
Berget, 2000). The role of GGGG is important for the regulation of GRIN1 splicing, as it 
was previously shown to be directly bound by hnRNP H (Han et al., 2005). In addition, 
the GGGG motif of the HNRNPH3 transcript was shown to be bound by hnRNP H 
(Stein, 2015), which further supports its role in hnRNP H-mediated splicing. For this 
reason, I asked whether the mutations in GGGG have an effect over the DRB-induced 
splicing changes in GRIN1 CI exon inclusion. In the GGGG motif mutants (5m2 and 
5m4), I observed a statistically significant increase in the effect of DRB, compared to 
that of the wild type (Figure 14). In untreated cells, GGGG it acts as a silencer, and the 
GGGG mutants have a big increase in GRIN1 CI exon inclusion (Figure 14). These data 
showed that the GGGG motif acts as an antagonist of the effect of DRB on the splicing 
of GRIN1 CI exon. 
3.2.4 DRB-induced alternative splicing reverses to untreated levels upon pause-
release in the pA+ reporter-transfected HeLa cells 
Transcriptional pausing is observed in a significant portion of genes in human and 
mouse embryonic stem cells (Guenther et al., 2007; Gilchrist et al., 2010). Pausing has 
a role in regulating the timing of gene expression, and the transcriptional pause release 
 73 
is possibly important in the regulation of alternative splicing. In addition, DRB-induced 
increase in exon skipping is a phenomenon worth investigating in detail about whether it 
is reversible, or if it is a permanent change in splicing patterns. Therefore, I decided to 
treat the pA+ reporter-transfected cells with DRB, and wash away the DRB, to check for 
the splicing upon transcriptional pause release. 
 
 
Figure 16: The silencing effect of DRB on the GRIN1 CI exon is reversible in the wild type pA+ 
splicing reporter-transfected HeLa cells. 250 ng of the wild-type pA+-C1wt0 was transfected into each 
well of HeLa cells, and after 4 hours the transfection medium was replaced by DMEM + 10% FBS 
including 0 µM or 30 µM DRB. Following the 14h DRB treatment, cells were either harvested (0 and 30 
µM samples) or washed with DMEM + 10% FBS and incubated at 37°C for 30m and 1h respectively. 
Total RNA was isolated, reverse transcribed, and PCR was performed with the primers recognizing the 
flanking exons of the GRIN1 CI cassette exon (26 cycles). PCR products were run on 1.8% agarose gel 
for 2 hours. The electrophoretic bands were analyzed by ImageGauge software. Numbers represent 
percentage of inclusion and skipping. ΔΨ (difference in PSI = Percent Spliced In) values show the 
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difference in percentage of inclusion; compared to 0 µM DRB. Asterisks above the column chart show 
statistically significant difference. Unpaired, two-tailed student’s t test was performed, and the changes in 
the GRIN1 CI inclusion were found to be statistically significant. (p < 0.05) 
 
Upon washing away the DRB, the splicing change that happened over the course 
of 14-hour DRB treatment was reversed (Figures 16, 17). In the GGGG motif mutants, I 
observed a rapid reversal in which the inclusion increased within only 1 hour after 
washing away the DRB in 5m2 and 5m4 (Figure 17). 
Also, the UAGG-GGGG splicing code was necessary for the splicing response to 
transcriptional pausing and pause release, because the E17 mutant had a diminished 
response to DRB and pause release, and T8 had no response at all (Figure 18). Beta 
actin-encoding transcript, ACTB, does not respond to the DRB treatment (Figure 19), 
showing the specificity of the effect of DRB, rather than a genomewide random 
perturbation of splicing. 
These data point to the effect of DRB on the splicing of HNRNPH1, HNRNPH3 
and GRIN1 through the action of hnRNP A1 and hnRNP H. In both cases, hnRNP H 
has a big effect on splicing. The combination of functional hnRNP A1 and hnRNP H 
motifs is necessary for the response to DRB, and GGGG is a strong silencer in CI. In 
HNRNPH3 exon 3, hnRNP H is a strong silencer and hnRNP A1 is an anti-silencer. The 
exonic UAGG - intronic GGGG code is present in HNRNPH1 exon 4 and HNRNPH3 
exon 3, supporting the role of hnRNP A1 and hnRNP H in the splicing response to DRB. 
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Figure 17: The silencing effect of DRB on GRIN1 CI exon is reversible, and it is faster in GGGG 
mutant than that of the wild type reporter-transfected HeLa cells. 250 ng of the A) pA+-5m2 or B) 
5m4 mutant was transfected into each well of HeLa cells, and after 4 hours the transfection medium was 
replaced by DMEM + 10% FBS including 0 µM or 30 µM DRB. Following the 14h DRB treatment, the 
wells were either harvested (0µM and 30µM samples) or washed with DMEM + 10% FBS and incubated 
at 37°C until the indicated pause-release time points. Total RNA was isolated, reverse transcribed, and 
PCR was performed with the primers recognizing the flanking exons of the GRIN1 CI cassette exon (26 
cycles). PCR products were run on 1.8% agarose gel for 2 hours. The electrophoretic bands were 
analyzed by ImageGauge software. Numbers represent percentage of inclusion and skipping. ΔΨ 
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(difference in PSI = Percent Spliced In) values show the difference in percentage of inclusion; compared 
to 0 µM DRB. Asterisks above the column chart show statistically significant difference. Unpaired, two-
tailed student’s t test was performed, and the changes in the GRIN1 CI inclusion were found to be 
statistically significant. (p < 0.05) 
 
 
Figure 18: UAGG-GGGG splicing code is necessary for the splicing response to DRB-induced 
transcriptional pausing and pause-release. 250 ng of the A) pA+-E17 double; or B) T8 triple mutant 
was transfected into each well of HeLa cells (n = 3), and after 4 hours the transfection medium was 
replaced by DMEM + 10% FBS including 0 - 30 µM DRB. Following the 14h DRB treatment, the wells 
were either harvested (0µM and 30µM samples) or washed with DMEM + 10% FBS and incubated at 
37°C for 30m or 1h. Total RNA was isolated, reverse transcribed, and PCR was performed with the 
primers recognizing the flanking exons of the GRIN1 CI cassette exon (26 cycles). PCR products were 
run on 1.8% agarose gel for 2 hours. The electrophoretic bands were analyzed by ImageGauge software. 
Numbers represent percent inclusion and skipping. ΔΨ (difference in PSI = Percent Spliced In) values 
show the difference in percentage of inclusion; compared to 0 µM DRB. Asterisks above the column chart 
show statistically significant difference of the E17 mutant exon inclusion. Unpaired, two-tailed student’s t 
test was performed, and the changes in the GRIN1 CI inclusion were statistically significant (p < 0.05). 
The CI skipping of the T8 mutant was not quantifiable. 
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Figure 19: ACTB exon 2 does not respond to the DRB-induced transcription elongation inhibition 
in pA+ splicing reporter-transfected HeLa cells. 5m2 mutant was co-transfected with the 
pcDNA3.1/PKA/A1 plasmids into each well of HeLa cells, and after 4 hours the transfection medium was 
replaced by DMEM + 10% FBS including 0 µM or 30 µM DRB. Following the 14h DRB treatment, total 
RNA was isolated, reverse transcribed, and PCR was performed with the ACTB E1/E3 primers. PCR 
products were run on 1% agarose gel for 1 hour. The gel was visualized with ImageGauge. There is no 
ACTB exon 2 skipping upon DRB treatment or co-transfection with these plasmids. 
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4.0  DISCUSSION 
RNA splicing was elucidated as a mechanism of diversifying the proteome of the cell, 
and as a fast response system to multiple environmental inputs. Its impact in human 
development and disease is a more recent phenomenon, and cancer is among the very 
important diseases directly tied to the aberrant splicing due to cis-acting mutations and 
changes in the splicing factor stoichiometry, localization, or activity in trans. The hnRNP 
H family is important in this framework, due to its overexpression in different cancers. 
 The main finding of this study was the splicing repressor effect of DRB-induced 
transcription on the exons sharing the UAGG-GGGG splicing code. Our main question 
was to understand the role of hnRNP H in the response to genotoxic and transcriptional 
stress. Cisplatin-induced single stranded DNA damage and DRB-induced transcriptional 
pausing had a similar effect on the splicing of HNRNPH1 exon 4 and HNRNPH3 exon 3, 
whereas gamma irradiation-induced double strand breaks did not have an effect. That is 
a sign of transcriptional pausing-induced splicing changes. 
The effect of DRB-induced transcriptional pausing on splicing is not random, as 
the control exon (ACTB exon 2) did not respond to DRB. Pausing of transcription had a 
bigger effect when the 5’ splice site GGGG motif was destroyed, and the triple mutant 
that lacks the two exonic UAGGs and the 5’ splice site GGGG lost its ability to respond 
to DRB, meaning that the hnRNP A1-binding UAGG and hnRNP H-binding GGGG 
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motifs were necessary for the response to transcriptional pausing. Purified hnRNP H 
has the ability to bind to UAGG motifs, albeit with a lower affinity (Grabowski Lab, 
unpublished data), hinting about a possible competition by multiple splicing factors for 
the same RNA motif. 
One of the novel findings of this study was the autoregulation of HNRNPH3 Exon 
3 splicing by hnRNP H. This autoregulation, which leads to a transcript level regulation 
by alternative splicing, is a putative fine-tuning system that acts in the response to very 
diverse types of cellular stresses. The role of hnRNP A1 and hnRNP H on the splicing 
of GRIN1 transcript, and their responsiveness to stimuli were already previously studied 
in our lab (Han et al., 2005; An and Grabowski, 2007). Transcriptional stress was known 
to induce changes in splicing, but the role of the hnRNP H-binding GGGG motifs in 
response to transcriptional pausing and pause-release, along with the necessity of the 
previously found UAGG-GGGG splicing code for the response to transcriptional stress 
and its reversibility are among the novel findings of this study. 
The role of transcription stress on genomewide splicing alterations is a well-
studied field of research, that shapes our understanding of how the splicing machinery 
responds to erroneous changes in the cell homeostasis, possibly being part of a bigger 
general stress response. Different types of cellular stress, such as the KCl excitation of 
neurons, flavopiridol- or DRB-induced transcription inhibition, and cisplatin-induced DNA 
damage may not seem to share a lot in common; but they somewhat converge to give 
rise to similar changes in the splicing of human HNRNPH1 and its paralog HNRNPH3. 
These data suggest a stress-mediated splicing response pathway, adjusting the splicing 
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of several transcripts for sparing some time for the cells to recover the damage caused 
by stress, and contribute to the overall phenotype upon homeostatic changes. 
Previous studies by various research groups concluded that there are transcripts 
with higher exon inclusion upon transcription stress, such as the fibronectin EDI exon. 
These groups tried to explain the phenomenon with “recruitment coupling” (de la Mata 
et al., 2006) by asserting that the CTD (C-terminal domain) tail of RNA polymerase II 
takes a role of docking pad for the RNA processing factors, transferred onto the newly 
emerging nascent transcript; and also with “kinetic coupling” (de la Mata et al., 2003), in 
which these splicing factors have a longer temporal window period for performing their 
splicing regulation activity upon transcriptional pausing. However, these studies did not 
point to the role of a particular splicing factor in the regulation of splicing upon pausing 
or transcriptional stress. In addition, the transcriptional pause-release is known to be 
prevalent in stem cells (Guenther et al., 2007; Core et al., 2008; Gilchrist et al., 2010) as 
a possible regulator of timing, but its effects on the splicing were still unknown. 
In this study, I found that the intronic GGGG motif downstream of the 5’ splice 
site, which was previously shown to be directly bound by hnRNP H (Han et al., 2005), 
has a silencer effect on splicing, and masks the effect of DRB on the splicing of GRIN1 
CI exon. Mutations in the GGGG motif caused an increase in the splicing repressor 
effect of DRB. However, the mutations in the exonic hnRNP A1-binding UAGG motif 
seemed to counter the DRB effect. In the combinatorial mutants of the exonic UAGGs 
and the intronic GGGG, the response to DRB is completely lost. Both RNA motifs are 
required for the effect of DRB-induced transcriptional stress on splicing, suggesting a 
crosstalk between these motifs or a possible complex formation among the splicing 
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factors that bind to these motifs. The DRB-induced transcriptional stress and the 
putative crosstalk or complex formation between UAGG and GGGG upon this stress is 
still unknown, and it remains to be identified. 
In the case of HNRNPH1, I observed that the feedback regulation by hnRNP H is 
another way of splicing response to stress. It is possible to predict that one role of this 
splicing can be the dose-dependent adjustment of the hnRNP H protein level in the cell, 
affecting the splicing of hundreds of transcripts in a concerted fashion. Since the DRB-
induced skipping of the HNRNPH1 exon 4 leads to nonsense-mediated RNA decay, this 
splicing response acts as a switch that decides whether there will be more hnRNP H 
protein made in the cell, or less upon stress. It was previously shown that the hnRNP H 
overexpression was involved in a switch to more aggressive and metastatic phenotype 
in gliomas (LeFave et al., 2011), therefore the nonsense-mediated decay of the hnRNP 
H transcript levels and fine-tuning of its splicing upon stress is important to keep the cell 
proliferation rate and phenotype on track. In order to address whether the splicing shift 
is a result of nonsense-mediated decay, UPF1 knockdown can be performed before the 
DRB-induced transcriptional stress. 
Our analysis of different mutants revealed that the G stretch acts as a silencer. 
Two different mutants at this location had a bigger response to DRB treatment, showing 
that the binding of the hnRNP H protein to wild-type GGGG motif causes increased 
skipping of the HNRNPH1 Exon 4, albeit smaller. However, the increase in E4 skipping 
was much higher when hnRNP H fails to bind to the mutant GGGG motif. That motif 
might have an indirect role in optimizing the hnRNP H abundance in the cell, or act as a 
stress sensor, depending on the stoichiometry of hnRNP H protein. In order to validate 
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the effect of the hnRNP H, it can be knocked down prior to DRB-induced transcriptional 
stress. Since hnRNP H is a silencer of HNRNPH3 exon 3, and since I know that GGGG 
mutants had a much bigger effect on splicing, I would speculate that it can increase the 
DRB-induced skipping. In order to test whether there are other RNA motifs that act via 
hnRNP H binding, hnRNP H knockdown or overexpression can be combined with the 
GGGG mutants, to check the effect of DRB-induced transcriptional stress on splicing. 
 The 5’ splice site GGGG was previously published to have a role in the strength 
and functionality of the 5’ splice site, and act as an enhancer (McCullough and Berget, 
1997; McCullough and Berget, 2000). However, I observed that it acts as a silencer for 
GRIN1 CI exon. This can be due to the interference of U1 snRNP, as it binds to a very 
close vicinity of the GGGG motif. U6 snRNP or other spliceosome components can also 
contribute to the effect of DRB-induced transcriptional stress in splicing. 
 The UAGG and GGGG mutations in GRIN1 CI exon were shown to be important 
in elucidating the effect of hnRNP H on the fine-tuning of splicing upon transcriptional 
stress. Since I observed that hnRNP H is a silencer acting on its own transcript, hnRNP 
H-encoding transcripts can be used in future experiments for constructing a splicing 
reporter, and performing site-directed mutagenesis on the exonic UAGG and intronic 
GGGG of HNRNPH1 exon 4 and HNRNPH3 exon 3. These mutants can be combined 
with transcriptional stress and the stoichiometric changes of hnRNP H by knockdown or 
overexpression, to test the changes in splicing. 
The levels of the HNRNPH1 and the HNRNPH3 transcripts can be regulated via 
nonsense-mediated decay in the absence of the intact GGGG motif, and the HNRNPH2 
can compensate the decreases in the levels of HNRNPH1 and HNRNPH3. The hnRNP 
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H2 is not subject to alternative splicing upon stress, making it a constantly available 
supply to perform the splicing regulation function of the hnRNP H family. The alternative 
splicing of hnRNP H1 and H3 leads to the shifts in the basal levels of hnRNP H proteins 
available in cells, contributing to the overall proliferative phenotype by acting upon the 
splicing of proliferation-associated transcripts, such as Bcl-x. 
Transcriptional pausing and pause-release are directly tied to the SR family of 
splicing factors. SRSF1 and SRSF2 were found to be associated with specific gene 
promoters and RNA sequences, specifically with hnRNP H1 gene and its transcript (Ji 
et al., 2013). In the RNA maps that I constructed, the SRSF1 and SRSF2 binding sites 
were at the very close vicinity of the hnRNP H and hnRNP A1 binding sites, hinting at a 
possible interaction or competition between these splicing factors. SRSF1 and SRSF2, 
as well as several hnRNPs, were found to be part of the 7SK non-coding RNA complex, 
acting as a link between the P-TEFb and the RNA polymerase II. SRSF2 has a specific 
role in RNA polymerase II CTD Ser2 phosphorylation and in CDK9-7SK association (Ji 
et al., 2013). The role of SRSF2 in the transcriptional pausing and pause-release, along 
with its roles in splicing, suggests that the DRB-induced effects that I observed on 
HNRNPH1-H3 and GRIN1 splicing can also be related to the roles of SR proteins on 
transcription-splicing coupling. Transcriptional activation of HNRNPH1 by SRSF2, and 
the autoregulation of HNRNPH3 splicing that I observed in this study, made me think 
that SR proteins and hnRNPs can act in an orchestrated fashion to control the level of 
gene expression and the accuracy of splicing as part of the 7SK complex in a promoter- 
and sequence-dependent, cooperative manner. 
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 Transcriptional pausing and its effect on splicing are also related to the 7SK RNA 
through the association of the 7SK complex with the hnRNP A1. Knocking down hnRNP 
A1/A2 resulted in a similar effect as DRB-induced inhibition of transcription elongation, 
which caused an increase in the 7SK-CDK9 interaction, changing the elongation rate 
(Lemieux et al., 2015). However, the role of the hnRNP H and the mechanism through 
which these hnRNPs act remains unsolved. Our triple mutant T8 that lacks two hnRNP 
A1- and one hnRNP H-binding sites, along with the double mutant E17 lacking two 
hnRNP A1 sites, had a truncated response to DRB. This result supported the previous 
data about the hnRNP A1/A2 knockdown mimicking DRB. However, our hnRNP A1 
knockdown did not affect HNRNPH3 splicing, possibly due to the presence of hnRNP H 
or hnRNP A2. In the case of GRIN1 CI exon, our GGGG mutants had a bigger response 
to DRB. HnRNP seemed to counter the effect of DRB, which remains unanswered. 
The changes in the GRIN1 splicing upon transcriptional stress and pause-release 
are particularly important, due to the roles of NMDA R1 receptor in learning, memory, 
neuronal and synaptic plasticity. Embryonic stem cells or other types of quickly-dividing 
cells go through different cellular stresses, in part due to differential access to nutrients 
or oxygen, random or induced mutations, or the transcriptional pausing as a way of the 
timing regulation of gene expression. The regulation of GRIN1 splicing upon pausing or 
pause-release confers a survival advantage by rapidly changing the synapses and the 
availability of the NMDA R1 receptors on the surface. Cellular stresses can contribute to 
learning and memory through the alternative splicing changes in GRIN1, and this novel 
hnRNP H-regulated stress response has a potential to have further roles in the brain. 
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This study answered some of the questions about the role of hnRNP H and the 
hnRNP H-binding GGGG motif in relation to the genotoxic and transcriptional stress as 
well as the pause-release, but it also has given rise to new questions. What is the role 
of hnRNP H in the recruitment coupling, or kinetic coupling? Does hnRNP H recognize 
a broader range of degenerate targets to influence the stress response? What is the 
effect of the weak-affinity interactions between hnRNP H and the UAGGG motifs that 
are known to be bound by hnRNP A1? What is the effect of the competition between 
hnRNP A1 and hnRNP H on the splicing response to stress? What is the result of the 
autoregulation of splicing by hnRNP H? Is there a genomewide regulation of splicing of 
the hnRNP H targets upon transcriptional stress and pause-release? Answering these 
questions will enable a broader understanding of how hnRNP H utilizes different stress 
inputs, turns them into a splicing readout and keeps the cellular homeostasis stable. 
In the future, a computational approach that will predict the targets of hnRNP H 
genomewide, and a transcriptomics approach to enrich the hnRNP H target transcripts 
and check their splicing in a global way would be interesting. By this way, the network of 
interactions or regulations as a target of hnRNP H in the presence versus absence of a 
transcriptional stress will be generated, and the stress-responsive targets of hnRNP H 
will be identified so as to elucidate the splicing cascade involved in the stress response. 
There are also unanswered questions about the functional output of hnRNP H-
mediated fine-tuning of splicing. What would be the resulting phenotype upon hnRNP H 
overexpression in primary cells? How do these cells respond to stress? If the response 
is masked via the presence of an intact GGGG motif and hnRNP H, how does the 
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knockdown of hnRNP H impact the transcriptional stress response of cancer cells? The 
combination of hnRNP H knockdown and DRB treatment can be applied. 
The direct binding of hnRNP H to GGGG motifs is known, but in this study, the 
binding of hnRNP H was not assayed with respect to DRB treatment. How is the affinity 
of hnRNP H binding to GGGG affected by DRB treatment in vitro? Does DRB affect the 
in vitro splicing of HNRNPH1 or HNRNPH3? What kind of a splicing pattern will their 
GGGG mutants have upon DRB treatment? DRB treatment of the cells with HNRNPH1 
and HNRNPH3 transcripts harboring GGGG mutations 
The pause-release and its reversible effect on GRIN1 splicing was important, but 
the limits of reversibility is not known. To what extent can the cells accommodate the 
transcriptional pausing and pause-release? Some transcripts can stay at transcriptional 
pausing for a very long time in embryonic stem cells. If we did the transcriptional stress 
and pause-release experiments with mouse embryonic stem cells, would we be able to 
change the fate of the cell? Can we force the differentiation of a pluripotent stem cell 
into a specific lineage by just applying DRB-induced transcriptional stress and controlled 
pause-release? Can we change the splicing patterns of iPS cells (induced pluripotent 
stem cells)? Is the splicing-transcription coupling an important aspect of development 
and cell fate determination? Is there a way of splicing adaptation to continuous stress in 
extreme environments, such as exposure to low-dose chemotherapeutic agents, UV, or 
ionizing radiation? Can cancer cells evolve upon exposure to continuous stresses within 
a tumor microenvironment, by rapidly changing the splicing behavior? 
On the whole, this study elucidated the role of hnRNP H in the autoregulation of 
its own splicing. In addition, I also determined the role of 5’ splice site-flanking GGGG 
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motif in transcriptional pausing and pause-release. Despite the remaining unknowns on 
the role of hnRNP H in the broad stress-sensing and splicing response upon stress, the 
cis RNA motif and the role of hnRNP H in trans for the response to transcriptional pause 
and pause-release were identified. The outcomes of this study can open the door for 
new experiments to understand the role of hnRNP H in the stress response pathways 
and stress-induced splicing regulation more in depth. 
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FLAVOPIRIDOL HAS A SMALL EFFECT ON THE SPLICING OF HNRNPH1 EXON 4 
Figure 20: Flavopiridol has a small effect on the splicing of HNRNPH1 Exon 4. 100 nM FVP was 
added on the HeLa cells for the indicated time points, and the effect was very small. The dose and the 
duration of the treatment can be increased, or a very high dose can be applied for a short interval to see 
its effect on splicing. 
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PKA AND HNRNP A1 CAUSE A SMALL INCREASE IN UNTREATED HELA CELLS, 
WITH A SLIGHT ANTAGONIZING EFFECT ON DRB 
Figure 21: PKA and hnRNP A1 cause a small increase in untreated HeLa cells, with a slight 
antagonizing effect on DRB. The pcDNA3 vbb, pcDNA3.PKA and pcDNA3.hnRNP A1 plasmids were 
transfected to HeLa cells, and the cells were treated with 0 or 30 µM DRB. The PCR was performed with 
the primers for the GRIN1 CI amplification. 
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PKA AND HNRNP A1 CAUSE A SMALL INCREASE IN CI SKIPPING IN THE 5M2-
TRANSFECTED HELA CELLS, WITH NO ANTAGONIZING EFFECT ON DRB-
MEDIATED SILENCING 
Figure 22: PKA and hnRNP A1 cause a small increase in CI skipping in the 5m2-transfected HeLa 
cells, with no antagonizing effect on DRB-mediated silencing. The pcDNA3 vbb, pcDNA3.PKA and 
pcDNA3.hnRNP A1 plasmids were transfected to HeLa cells, and the cells were treated with 0 or 30 µM 
DRB. The PCR was performed with the primers for the GRIN1 CI amplification. 
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PKA OVEREXPRESSION CAUSES A DELAY IN THE DRB PAUSE-RELEASE IN 
5M2-TRANSFECTED HELA CELLS 
Figure 23: PKA overexpression causes a delay in the DRB pause-release in 5m2-transfected HeLa 
cells. The pcDNA3 vbb, pcDNA3.PKA and pcDNA3.hnRNP A1 plasmids were transfected to HeLa cells, 
and the cells were treated with 0 or 30 µM DRB. The PCR was performed with the primers for the GRIN1 
CI amplification. After the 14h DRB treatment, the cell medium was replaced by DMEM+10% FBS lacking 
DRB. 
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